[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 350
1. Chowdhary A, Ahmad S, Khan ZU, Doval DC, Randhawa HS: Trichosporon asahii as an emerging etiologic agent of disseminated trichosporonosis: a case report and an update. Indian J Med Microbiol; 2004 Jan-Mar;22(1):16-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To report a fatal case of disseminated trichosporonosis caused by Trichosporon asahii in a patient with acute myeloblastic leukemia (AML) and to present an update on systemic trichosporonosis with special reference to India.
  • METHODS: The diagnosis was based on repeated demonstration of budding yeast cells and arthroconidia by direct microscopic examination of sputum and by isolation of T. asahii in culture of sputum and blood.
  • RESULTS: A 41-year-old male presented with acute myeloblastic leukemia, cough and fever.
  • He had received cytotoxic drug therapy, broad spectrum antibiotics and was neutropenic.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642680.001).
  • [ISSN] 0255-0857
  • [Journal-full-title] Indian journal of medical microbiology
  • [ISO-abbreviation] Indian J Med Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


2. Mashita T, Shimoda T, Yoshioka H, Takahashi Y, Mitsuda M: A cat with acute myeloblastic leukemia without maturation (M1) treated with combination chemotherapy. J Vet Med Sci; 2006 Jan;68(1):97-101
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cat with acute myeloblastic leukemia without maturation (M1) treated with combination chemotherapy.
  • The blastic cells were shown to be positive for peroxidase.
  • Acute myeloblastic leukemia without maturation (M1) was diagnosed according to the FAB classification.
  • Chemotherapy was initiated with cyclophosphamide, vincristine, prednisolone, and cytosine arabinoside.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462128.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


3. Cohen Y, Amir G, Da'as N, Gillis S, Rund D, Polliack A: Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis. Am J Hematol; 2002 Sep;71(1):47-9
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.
  • This case report deals with an unusual leukostatic complication in a 56-year-old woman with acute myeloblastic leukemia (AML) and extreme hyperleukocytosis (316 x 10(9)/L) who presented with acute myocardial infarction (MI).
  • After leukopheresis the patient achieved hemodynamic stabilization and rapid neurologic recovery of encephalopathy that had also developed after the infarction.
  • Considering the central role of WBC in the remodeling of post MI myocardial tissue, it was obvious that administration of chemotherapy with its subsequent inevitable pancytopenia could impose an increased risk for further cardiac complications including myocardial rupture.
  • Nevertheless, cytarabine-based induction chemotherapy was initiated 3 days after admission, and she achieved prolonged complete remission.
  • The patient died with relapsed leukemia 7 years later without recurrence of any cardiac symptoms or signs.
  • Additional compromise to blood perfusion due to leukostasis had led to this unusual complication of AML involving a major vessel.
  • This is the first documented case of leukostasis causing coronary artery occlusion as well as the first report of successful induction chemotherapy for AML during a myocardial infarction.
  • [MeSH-major] Aminoglycosides. Leukemia, Myeloid, Acute / complications. Leukocytosis / etiology. Myocardial Infarction / etiology
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antigens, CD / immunology. Antigens, Differentiation, Myelomonocytic / immunology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Confusion / etiology. Confusion / therapy. Cytarabine / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Female. Humans. Idarubicin / administration & dosage. Immunotherapy. Leukapheresis. Middle Aged. Mitoxantrone / administration & dosage. Recurrence. Remission Induction. Salvage Therapy. Sialic Acid Binding Ig-like Lectin 3. Therapeutics. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12221675.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Anti-Bacterial Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / gemtuzumab; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


Advertisement
4. Jourdan E, Boiron JM, Dastugue N, Vey N, Marit G, Rigal-Huguet F, Molina L, Fegueux N, Pigneux A, Recher C, Rossi JF, Attal M, Sotto JJ, Maraninchi D, Reiffers J, Bardou VJ, Esterni B, Blaise D: Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. J Clin Oncol; 2005 Oct 20;23(30):7676-84
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience.
  • PURPOSE: We analyzed the impact of allogeneic stem-cell transplantation (alloSCT) as an early consolidation for young patients with acute myeloblastic leukemia in first complete remission (CR1) through four successive protocols.
  • CONCLUSION: AlloSCT was associated with a survival advantage for an intermediate-risk group.
  • In other groups, numbers are limited for definitive conclusion.
  • However, early performed alloSCT does not seem to be the optimal treatment of high-risk patients or offer any advantage over intensive chemotherapy in low-risk patients.
  • [MeSH-major] Leukemia, Myeloid / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prospective Studies. Remission Induction. Time Factors. Tissue and Organ Procurement. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16186596.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


5. Krauter J, Hoellge W, Wattjes MP, Nagel S, Heidenreich O, Bunjes D, Ganser A, Heil G: Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR. Genes Chromosomes Cancer; 2001 Apr;30(4):342-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR.
  • We used a newly established real-time RT-PCR assay for the quantification of the leukemia-specific CBFB/MYH11 transcripts in inv(16)-positive acute myeloblastic leukemia.
  • CBFB/MYH11 could be quantified over a five log range, with a detection limit of 10 molecules of a CBFB/MYH11 plasmid and a 1:10(5) dilution of RNA of the inv(16)-positive ME-1 cell line, respectively.
  • The fusion transcripts were also quantified in 19 patients with acute myeloblastic leukemia and an inv(16) at initial diagnosis.
  • The expression of CBFB/MYH11 varied over a two log range without correlation to clinical response or relapse rate.
  • In nine patients, CBFB/MYH11 was also quantified during/after chemotherapy and autologous or allogeneic stem cell transplantation.
  • All of these patients showed a similar decline of CBFB/MYH11 after intensive therapy.
  • Six of these patients are in complete remission with a stable low-level or absent CBFB/MYH11 expression.
  • In two patients, this increase in CBFB/MYH11 could be detected by real-time PCR before hematological relapse.
  • These data indicate that real-time RT-PCR can be used for the sensitive detection and quantification of CBFB/MYH11 transcripts in the follow-up of patients with inv(16)-positive AML.
  • [MeSH-major] Chromosome Inversion. Chromosomes, Human, Pair 16 / genetics. Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / analysis. Oncogene Proteins, Fusion / genetics. Polymerase Chain Reaction / methods. RNA, Messenger / analysis. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11241787.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CBFbeta-MYH11 fusion protein; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger
  •  go-up   go-down


6. Klossek A, Dannenberg C, Feuerhahn MR, Körholz D: Pulmonary tuberculosis in a child receiving intensive chemotherapy for acute myeloblastic leukemia. J Pediatr Hematol Oncol; 2004 Jan;26(1):64-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary tuberculosis in a child receiving intensive chemotherapy for acute myeloblastic leukemia.
  • The authors describe a 6-year-old boy who developed pulmonary tuberculosis during intensive chemotherapy for acute myeloblastic leukemia (AML).
  • The diagnosis of tuberculosis was made by PCR from an open lung biopsy, while a bacterial culture was negative.
  • The patient was treated with triple tuberculostatic drug therapy, followed by two-drug therapy, while receiving maintenance chemotherapy for AML, including thioguanine and cytarabine.
  • Pulmonary infiltrates resolved within 2 months of treatment.
  • However, possibly due to the bone marrow toxicity of the tuberculostatic drugs, the patient tolerated only low doses of cytostatic therapy.
  • The boy is now 14 months off tuberculostatic treatment and 8 months off AML therapy.
  • He is in remission of AML and tuberculosis.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Myeloid, Acute / complications. Tuberculosis, Pulmonary / chemically induced
  • [MeSH-minor] Antitubercular Agents / therapeutic use. Child. Disease-Free Survival. Humans. Male. Molecular Diagnostic Techniques. Polymerase Chain Reaction. Remission Induction

  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14707718.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antitubercular Agents
  •  go-up   go-down


7. Pallis M, Grundy M, Turzanski J, Kofler R, Russell N: Mitochondrial membrane sensitivity to depolarization in acute myeloblastic leukemia is associated with spontaneous in vitro apoptosis, wild-type TP53, and vicinal thiol/disulfide status. Blood; 2001 Jul 15;98(2):405-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitochondrial membrane sensitivity to depolarization in acute myeloblastic leukemia is associated with spontaneous in vitro apoptosis, wild-type TP53, and vicinal thiol/disulfide status.
  • Nonresponse to remission-induction chemotherapy, which remains a major problem in acute myeloblastic leukemia (AML), has been linked to cellular resistance to apoptosis.
  • Because the apoptosis induced by chemotherapeutic drugs is mediated by loss of mitochondrial transmembrane potential (MTP), it was postulated that sensitivity to mitochondrial membrane depolarization might be heterogeneous in AML.
  • Using the uncoupling agent carbonyl cyanide m-chlorophenylhydrazone (mClCCP), the mitochondrial membrane sensitivity to depolarization (mClCCP concentrations that inhibit 50% of the transmembrane potential [IC(50)]) in AML blasts was measured and demonstrated marked interclonal heterogeneity, with the existence of comparatively sensitive (median mClCCP IC(50), 4 microM) and resistant (median mClCCP IC(50), 10 microM) clones.
  • To confirm that TP53 directly affects MTP in leukemic cells and to establish the role of vicinal thiol oxidation in the TP53-dependent pathway, CEM 4G5 leukemia cells with forced, temperature-dependent expression of TP53 were studied.
  • It was concluded that in leukemia, TP53 and vicinal thiol/disulfide status are determinants of mitochondrial membrane sensitivity to depolarization, which is in turn associated with spontaneous apoptosis.
  • [MeSH-major] Apoptosis. Intracellular Membranes / physiology. Leukemia, Myeloid, Acute / pathology. Mitochondria / ultrastructure. Sulfhydryl Compounds / metabolism. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Carbocyanines. Carbonyl Cyanide m-Chlorophenyl Hydrazone / pharmacology. Disulfides / metabolism. Fluorescent Dyes. Humans. Maleates / pharmacology. Membrane Potentials / drug effects. Mutation. Oxidation-Reduction. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Tumor Cells, Cultured. Uncoupling Agents / pharmacology. bcl-2-Associated X Protein. bcl-X Protein

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11435310.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / BCL2L1 protein, human; 0 / Carbocyanines; 0 / Disulfides; 0 / Fluorescent Dyes; 0 / Maleates; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Sulfhydryl Compounds; 0 / Tumor Suppressor Protein p53; 0 / Uncoupling Agents; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein; 54501-79-0 / 3,3'-dihexyl-2,2'-oxacarbocyanine; 555-60-2 / Carbonyl Cyanide m-Chlorophenyl Hydrazone; G81WQB56OL / diethyl maleate
  •  go-up   go-down


8. Matsui K, Tanaka Y, Yamashita K, Matsuda K, Shinohara K: Acute myeloblastic leukemia in a patient with hereditary protein C deficiency. Intern Med; 2006;45(11):729-32
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloblastic leukemia in a patient with hereditary protein C deficiency.
  • She recently developed acute myeloblastic leukemia (AML).
  • Chemotherapy for AML by cytosine arabinoside, aclarubicin followed by granulocyte colony-stimulating factor (CAG) was started.
  • Whether the development of these rare disorders of hereditary protein C and AML are coincidental, or involve a causal relationship remains unknown.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Aclarubicin / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / therapeutic use. Enterocolitis, Pseudomembranous / etiology. Enterocolitis, Pseudomembranous / pathology. Fatal Outcome. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Middle Aged. Protein C Deficiency / complications. Protein C Deficiency / drug therapy. Protein C Deficiency / pathology

  • Genetic Alliance. consumer health - Protein C Deficiency.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16819254.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 74KXF8I502 / Aclarubicin; CAG protocol
  •  go-up   go-down


9. Hsu HC, Lee YM, Tsai WH, Jiang ML, Ho CH, Ho CK, Wang SY: Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology; 2002;63(1):64-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome.
  • The regulatory mechanism of endogenous cytokines in circulating platelet counts of thrombocytopenic patients with acute myeloblastic leukemia (AML) and myelodysplastic syndrome (MDS) is still not clear.
  • METHODS: We measured the serum levels of both thrombopoietic and inflammatory cytokines in peripheral blood and bone marrow samples collected from 52 patients with either AML or MDS along with 35 normal control samples.
  • RESULTS: Platelet counts in the AML/MDS patients during initial diagnosis, chemotherapy and complete remission were 71.2 +/- 11.6, 47.2 +/- 6.1 and 181.4 +/- 26.3 x10(9)/l, respectively.
  • The median value of TPO in AML/MDS patients during diagnosis was 150.6 pg/ml and increased significantly during chemotherapy (median: 828 pg/ml; p < 0.05) but then decreased following complete remission (median: 221.4 pg/ml).
  • However, these levels were all significantly higher in patients than in normal subjects (p < 0.05, p < 0.05 and p < 0.05; respectively), and no significant change was noted in the levels of IL-11 and SCF during treatment of patients or in normal controls.
  • The level of IL-6 was not detectable in normal serum samples but was markedly increased in the AML/MDS patients (median level during diagnosis: 6.7 pg/ml; chemotherapy: 25 pg/ml; complete remission: 7 pg/ml).
  • The level of IL-8 in patients with AML and MDS was markedly elevated during diagnosis (median: 27.5 pg/ml; range: 0-1,587 pg/ml), but decreased to the level of the normal controls when patients were under chemotherapy or in complete remission.
  • CONCLUSIONS: The endogenous levels of TPO, IL-6 and IL-8 are elevated in the thrombocytopenic patients with AML and MDS.
  • [MeSH-major] Cytokines / blood. Leukemia, Myeloid, Acute / blood. Myelodysplastic Syndromes / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Drug Therapy. Humans. Interleukin-11 / blood. Interleukin-6 / blood. Interleukin-8 / blood. Middle Aged. Platelet Count. Stem Cell Factor / blood. Thrombopoietin / blood


10. Preisler HD, Venugopal P, Gregory SA, Adler S, Gezer S, Hsu WT, Manson S, Larson A, Jajeh A, Slvinick D, Galvez A: High remission rate in acute myeloblastic leukemia with only two days of chemotherapy. Leuk Lymphoma; 2001 Apr;41(3-4):333-6
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High remission rate in acute myeloblastic leukemia with only two days of chemotherapy.
  • Twenty five patients with AML who had neither a history of toxic exposure or myelodysplasia were treated with a remission induction regimen consisting of two pulses of chemotherapy separated by 96 hrs.
  • Amifostine was administered three times a week [on Monday, Wednesday, and Friday] until the outcome of therapy was known.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cohort Studies. Cytarabine / administration & dosage. Cytarabine / standards. Cytogenetic Analysis. Drug Administration Schedule. Humans. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / standards. Remission Induction. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11378545.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


11. Saito Y, Ishikawa S, Endo H, Sato Y, Susukida I, Suzuki S, Uzuka Y: [A long-term survivor after relapsed acute myeloblastic leukemia with anthracycline dilated cardiomyopathy]. Gan To Kagaku Ryoho; 2008 Jun;35(6):1021-4
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long-term survivor after relapsed acute myeloblastic leukemia with anthracycline dilated cardiomyopathy].
  • We watched and analyzed patient cardiac functions especially with a "Phased tracking method" to detect rapid motion of the heart.
  • The patient suffered from congestive heart failure while depending on anthracycline cumulative doses, but now has been living more than 10 years after relapsed acute myeloblastic leukemia.
  • To avoid congestive heart failure with increasing highly tumoricidal anthracycline doses, cardiac function should be monitored closely in connection with treatment schedules and proposed accurate therapeutic index.
  • [MeSH-major] Anthracyclines / adverse effects. Anthracyclines / therapeutic use. Cardiomyopathy, Dilated / chemically induced. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Aged. Female. Humans. Recurrence. Time Factors

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • Genetic Alliance. consumer health - Dilated Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633238.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anthracyclines
  •  go-up   go-down


12. Carral A, de la Rubia J, Martín G, Mollá S, Martínez J, Sanz GF, Soler MA, Jarque I, Jiménez C, Sanz MA: Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and non-myeloid malignancies. Leuk Res; 2003 Jan;27(1):5-12
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and non-myeloid malignancies.
  • Factors influencing the collection of autologous peripheral blood stem cells (PBSCs) were studied in 182 mobilization procedures performed on 145 consecutive patients with acute myeloblastic leukemia (AML; n=67) and with various non-myeloid malignancies (NMM; n=78).
  • PBSC were collected following mobilization with chemotherapy, treatment with granulocyte colony-stimulating factor (G-CSF) or chemotherapy plus G-CSF.
  • Fewer colony-forming unit granulocyte-macrophages (CFU-GMs) were collected from patients with AML than from patients with NMM (P<0.0001), although there were no differences in the numbers of CD34+ cells collected between both groups.
  • Multiple regression analysis showed that chemotherapy alone was predictive of a low CD34+ yield in patients with NMM (regression coefficient (RC)=-2.1; P=0.003).
  • In addition, the interactions "diagnosis mutliple myeloma (MM)xmobilization with chemotherapy" (RC=2.9; P=0.004) and "diagnosis MMxmobilization with chemotherapy plus G-CSF" (RC=2.1; P=0.04) also remained in the model, both showing a favorable influence.
  • In AML, mobilization with chemotherapy plus G-CSF was associated with higher CD34+ yields (P=0.003).
  • In this subgroup of patients, multiple regression analysis identified the number of cycles of previous chemotherapy (< or =2 cycles; RC=1.3; P=0.03) and peripheral blood counts (WBC > or =1.5 x 10(9)/l and monocytes >20%; RC=0.8; P=0.02) as the factors most predictive of CD34+ cell yield.
  • These findings emphasize the need to optimize harvesting technique to enhance safety and minimize morbidity and costs of this valuable procedure.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Granulocyte Colony-Stimulating Factor / pharmacology. Hematopoietic Stem Cell Mobilization. Leukemia, Myeloid / blood. Neoplasms / blood. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Blood Cell Count. Bone Marrow / drug effects. Bone Marrow / radiation effects. Colony-Forming Units Assay. Drug Synergism. Female. Humans. Leukapheresis / instrumentation. Leukapheresis / methods. Male. Middle Aged. Radiotherapy / adverse effects. Regression Analysis. Retrospective Studies. Safety. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12479846.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


13. Kumar L, Menon H, Sharma A, Wadhwa J, Kumar R, Kochupillai V: Acute myeloid leukemia (AML): A study of 516 patients. J Clin Oncol; 2004 Jul 15;22(14_suppl):6711

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia (AML): A study of 516 patients.
  • : 6711 Background: To review the clinical presentation and treatment outcome.
  • METHODS: This is a retrospective audit of 516 AML patients seen in the 'Leukemia Clinic' between Jan.1991 and Dec. 2000.
  • FAB subtype revealed- M0 (0.4%), M1(10.7%)., M2 (26.4%), M3 (6%), M4 (15.3%), M5 (14.7%), M6 (4%), M7(0.8%).
  • Subtype was not known in 20% and 2.7% of patients had secondary AML.
  • 266 (51.6%) patients received induction chemotherapy (CT) using 3:7 (80.5%) or 2:5 (7%) or 3:7 + ATRA (3%), low dose Ara-C (6.7%) or others.
  • The median overall (OS) & leukemia-free survival (LFS) for treated patients is 13.2 and 10.4 months, respectively.
  • Comparison between two time periods (1991-1995) and 1996-2000) revealed improvement in both OS (8.8% vs 17%) and LFS (15% vs 25%,p<.05).
  • CONCLUSIONS: Our patients were young and had higher leukemia burden (WBC count >30,000/cmm in >50%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014702.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Mueller M, Calvo AR: Acute Shoulder Monoarthritis in a Patient With Acute Myelomonocytic Leukemia With Novel Translocation t(5;13). World J Oncol; 2010 Feb;1(1):50-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute Shoulder Monoarthritis in a Patient With Acute Myelomonocytic Leukemia With Novel Translocation t(5;13).
  • We present the case of a patient with acute myelomonocytic leukemia with trisomy 8 and novel translocation t(5;13).
  • In addition to acute leukemia she had debilitating left shoulder arthritis due to granulocytic sarcoma formation in the joint space.
  • Her shoulder pain did not improve during induction chemotherapy but she experienced rapid relief of symptoms with use of local radiation.
  • Her leukemia was found to be primary refractory to chemotherapy and despite an attempt at salvage therapy she died 2 months after diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Rheumatol. 1992 Mar;19(3):481-4 [1578467.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Skeletal Radiol. 1997 Jan;26(1):70-2 [9040149.001]
  • [Cites] Arch Pathol Lab Med. 1977 Apr;101(4):203-5 [265696.001]
  • [Cites] J Clin Rheumatol. 2000 Dec;6(6):313-7 [19078491.001]
  • [Cites] J Rheumatol. 1991 Feb;18(2):293-6 [1827162.001]
  • [Cites] Skeletal Radiol. 2007 Jun;36(6):547-50 [17187288.001]
  • [Cites] J Korean Med Sci. 1987 Dec;2(4):255-8 [3268183.001]
  • [Cites] J Rheumatol. 1983 Feb;10(1):132-5 [6573513.001]
  • [Cites] Semin Arthritis Rheum. 1994 Aug;24(1):48-56 [7985037.001]
  • [Cites] Diagn Mol Pathol. 2000 Dec;9(4):190-4 [11129442.001]
  • [Cites] Ann Hematol. 2006 Oct;85(10):741-2 [16718497.001]
  • [Cites] Arch Intern Med. 1981 Aug;141(9):1183-7 [6942790.001]
  • [Cites] Head Neck. 1990 Nov-Dec;12(6):507-11 [2258291.001]
  • (PMID = 29147181.001).
  • [ISSN] 1920-454X
  • [Journal-full-title] World journal of oncology
  • [ISO-abbreviation] World J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; 13) / Acute myelogenous leukemia / Arthritis / Hypercalcemia / t(5
  •  go-up   go-down


15. Winton EF, Langston AA: Update in acute leukemia 2003: a risk adapted approach to acute myeloblastic leukemia in adults. Semin Oncol; 2004 Apr;31(2 Suppl 4):80-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update in acute leukemia 2003: a risk adapted approach to acute myeloblastic leukemia in adults.
  • Acute myeloblastic leukemia represents a heterogeneous group of diseases.
  • The diagnosis and prognosis is most accurately provided by pretreatment assessment of the clonal molecular genetic derangement responsible for the disease, often provided by cytogenetic analysis.
  • Other prognostic features include patient age, antecedent myelodysplasia, prior chemotherapy, and the presence of FLT-3 mutations.
  • Accurate assessment of prognosis permits a risk-adapted treatment approach to maximize probability of cure and minimize treatment-related toxicity.
  • The majority of patients with promyelocytic leukemia with the PML/RARalpha fusion gene can be cured with an all-trans-retinoic acid and anthracycline-based treatment program.
  • All other patients are typically given cytarabine and anthracycline-containing induction regimens, although some with particularly poor prognosis disease may be more appropriate candidates for experimental induction therapies.
  • Postinduction treatments include further conventional chemotherapy, stem cell transplant strategies, and experimental approaches.
  • Issues pertinent in selecting treatments for patients in the different risk categories are reviewed.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Humans. Prognosis. Risk

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15124139.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 37
  •  go-up   go-down


16. Beyan C, Kaptan K, Cetin T, Nevruz O: Severe hyperglycemia as a complication of big ICE chemotherapy in a patient with acute myeloblastic leukemia. Haematologia (Budap); 2002;32(4):505-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe hyperglycemia as a complication of big ICE chemotherapy in a patient with acute myeloblastic leukemia.
  • BACKGROUND: Big ICE chemotherapy (consisting of Idarubicin, high dose Cytosine arabinoside and Etoposide), has proven its efficacy in the treatment of patients with relapse/refractory acute myeloblastic leukemia.
  • In this case report, we present a patient developing the complication of severe hyperglycemia following administration of big ICE because of a relapse of acute myeloblastic leukemia.
  • CASE REPORT: When a 41-year-old woman with acute myeloblastic leukemia in relapse was treated using the big ICE protocol, because of lack of efficacy of other chemotherapy regimens.
  • On the 7th day and 9th day of chemotherapy, glycemia was 13.2 mmol/l and 25.8 mmol/l, respectively.
  • After the regulation of the glycemia, regular insulin was injected four times daily.
  • CONCLUSION: Severe hyperglycemia/diabetes mellitus likely due to chemotherapy may develop in patients with acute leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cytarabine / adverse effects. Etoposide / adverse effects. Hyperglycemia / chemically induced. Idarubicin / adverse effects. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Blood Glucose / metabolism. Female. Humans. Insulin / therapeutic use. Recurrence. Time Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12803126.001).
  • [ISSN] 0017-6559
  • [Journal-full-title] Haematologia
  • [ISO-abbreviation] Haematologia (Budap)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Insulin; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; ZRP63D75JW / Idarubicin; ICE protocol 4
  •  go-up   go-down


17. Rüping MJ, Vehreschild JJ, Cornely OA: Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question? Leuk Lymphoma; 2010 Jan;51(1):20-6
Hazardous Substances Data Bank. CASPOFUNGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question?
  • In this review, we aim to compare different early treatment strategies of invasive fungal diseases in patients undergoing induction chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
  • Three treatment approaches--prophylactic, empiric, and preemptive treatment--are subject to continuous discussion among physicians treating patients at risk.
  • Considering the available clinical basis of evidence, we opt for antifungal prophylaxis with posaconazole 200 mg tid po as our primary prophylactic strategy, while the employment of preemptive treatment should be delayed until more accurate diagnostic tools become available.
  • In addition to antifungal prophylaxis, empiric treatment with caspofungin or L-AmB may be administered to patients with fever resistant to broad-spectrum antibiotic treatment and without radiographic findings typical of invasive fungal disease.
  • [MeSH-major] Antifungal Agents / therapeutic use. Leukemia, Myeloid, Acute / complications. Mycoses / complications. Mycoses / drug therapy. Myelodysplastic Syndromes / complications
  • [MeSH-minor] Amphotericin B / therapeutic use. Anti-Bacterial Agents / therapeutic use. Clinical Trials as Topic. Drug Resistance, Fungal. Echinocandins / therapeutic use. Fever / drug therapy. Humans. Medical Oncology / methods. Triazoles / therapeutic use

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2011 Feb;52(2):339-40 [21281242.001]
  • (PMID = 20017598.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antifungal Agents; 0 / Echinocandins; 0 / Triazoles; 0 / liposomal amphotericin B; 6TK1G07BHZ / posaconazole; 7XU7A7DROE / Amphotericin B; F0XDI6ZL63 / caspofungin
  • [Number-of-references] 51
  •  go-up   go-down


18. Kanda Y: [Mini-transplant for acute myeloblastic leukemia and myelodysplastic syndrome]. Nihon Rinsho; 2003 Sep;61(9):1565-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mini-transplant for acute myeloblastic leukemia and myelodysplastic syndrome].
  • Recently, non-myeloablative stem cell transplantation(NST) or reduced-intensity stem cell transplantation(RIST) has been developed as a less toxic HSCT, which enables the application of HSCT to patients of advanced age or with organ dysfunction by the use of mild conditioning regimen.
  • The anti-leukemia effect mainly depends on the graft-versus-leukemia (GVL) effect.
  • Several studies showed promising results of NST/RIST for acute myeloblastic leukemia(AML) and myelodysplastic syndrome(MDS).
  • However, this novel treatment is still very toxic compared to conventional chemotherapy.
  • We should continue clinical trials of NST/RIST to evaluate its efficacy and toxicity in patients with AML/MDS.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / therapy. Transplantation Conditioning
  • [MeSH-minor] Graft vs Leukemia Effect. Humans. Prognosis. Transplantation, Homologous


19. Liubimova LS, Akopian OG, Banchenko GV, Savchenko VG: [The effect of polychemotherapy on the oral mucosa in patients with acute myeloblastic leukemia]. Stomatologiia (Mosk); 2000;79(3):18-22
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The effect of polychemotherapy on the oral mucosa in patients with acute myeloblastic leukemia].
  • Oral mucosa was examined in 23 patients with acute myeloblastic leukemia before and after cytostatic polychemotherapy.
  • Lesions of the oral mucosa were observed in all patients after polychemotherapy: its color was changed, atrophic processes developed in it, and salivary secretion was impaired.
  • The study will help develop more effective approaches to prevention and treatment of oral complications and improve the results of therapy of this most grave category of hematological patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / complications. Mouth Mucosa / drug effects
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Leukocytes / drug effects. Leukopenia / blood. Leukopenia / chemically induced. Leukopenia / diagnosis. Male. Middle Aged. Stomatitis / blood. Stomatitis / chemically induced. Stomatitis / diagnosis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10850173.001).
  • [ISSN] 0039-1735
  • [Journal-full-title] Stomatologii︠a︡
  • [ISO-abbreviation] Stomatologiia (Mosk)
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] RUSSIA
  •  go-up   go-down


20. Qachouh M, Quessar A, Harif M, Benchekroun S: [Acute myeloblastic leukemia in adults: evaluation of the AML 06/96 protocol]. Tunis Med; 2003 Jul;81(7):461-5
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute myeloblastic leukemia in adults: evaluation of the AML 06/96 protocol].
  • [Transliterated title] Leucémies aigües myéloblastiques de l'adulte: évaluation du protocole AML 06/96.
  • The treatment of acute myeloid leukemia (AML) permits in a population of 25 to 60 years, a complete remission (CR) about 60 to 85% with relapse free survival at 5 years from 45 to 60%.
  • We report our therapeutic results during two years, from june 1996 to december 1998.
  • 104 patients with the novo AML treated according to AML 06/96 protocol, the mean age was 32.5 years old, from 16 to 55 years old.
  • 6 patients died before treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Lomustine / administration & dosage. Male. Middle Aged. Prospective Studies. Recurrence. Remission Induction. Time Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14534956.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 04079A1RDZ / Cytarabine; 7BRF0Z81KG / Lomustine; 80168379AG / Doxorubicin
  •  go-up   go-down


21. Wang HF, Cheng YZ, Wang HP, Chen ZM, Lou JY, Jin J: CD19-positive acute myeloblastic leukemia with trisomy 21 as a sole acquired karyotypic abnormality. J Zhejiang Univ Sci B; 2009 Nov;10(11):833-8
MedlinePlus Health Information. consumer health - Down Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD19-positive acute myeloblastic leukemia with trisomy 21 as a sole acquired karyotypic abnormality.
  • We report that a 63-year-old Chinese female had acute myeloblastic leukemia (AML) in which trisomy 21 (+21) was found as the sole acquired karyotypic abnormality.
  • A diagnosis of CD19-positive AML-M5 was established with trisomy 21 as a sole acquired karyotypic abnormality.
  • The patient did not respond well to chemotherapy and died three months after the diagnosis.
  • This is the first reported case of CD19-positive AML with trisomy 21 as the sole cytogenetic abnormality.
  • The possible prognostic significance of the finding in AML with +21 as the sole acquired karyotypic abnormality was discussed.
  • [MeSH-major] Antigens, CD19 / biosynthesis. Down Syndrome / genetics. Leukemia, Myeloid, Acute / genetics
  • [MeSH-minor] Antigens, CD / biosynthesis. Antigens, CD34 / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Bone Marrow Cells / metabolism. Female. HLA-DR Antigens / metabolism. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Karyotyping. Middle Aged. Peroxidase / metabolism. Sialic Acid Binding Ig-like Lectin 3. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 1999 Nov;23(11):1079-83 [10576514.001]
  • [Cites] Arch Med Res. 2007 Oct;38(7):797-802 [17845902.001]
  • [Cites] Cancer Genet Cytogenet. 2001 May;127(1):77-9 [11408071.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Mar;133(2):183-4 [11943351.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Jun;22(2):99-108 [3708552.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Nov;29(1):9-21 [3478133.001]
  • [Cites] Cancer Genet Cytogenet. 1989 Jul 15;40(2):203-16 [2766244.001]
  • [Cites] J Clin Oncol. 1990 Mar;8(3):423-30 [2307987.001]
  • [Cites] Am J Med Genet Suppl. 1990;7:247-50 [2149957.001]
  • [Cites] Am J Med Genet Suppl. 1990;7:262-6 [2149959.001]
  • [Cites] Blood. 1991 May 15;77(10):2242-50 [1709379.001]
  • [Cites] Leukemia. 1992 Mar;6(3):171-5 [1533007.001]
  • [Cites] Leukemia. 1992 May;6(5):393-9 [1375696.001]
  • [Cites] Blood. 1992 Nov 1;80(9):2210-4 [1384797.001]
  • [Cites] Leukemia. 1993 Apr;7(4):489-98 [7681917.001]
  • [Cites] Blood. 1993 May 1;81(9):2399-405 [7683218.001]
  • [Cites] Baillieres Clin Haematol. 1992 Oct;5(4):815-31 [1308166.001]
  • [Cites] Blood. 1993 Nov 15;82(10):3098-102 [8219201.001]
  • [Cites] Blood. 1994 Aug 15;84(4):1220-5 [8049437.001]
  • [Cites] Leukemia. 1995 Jan;9(1):115-7 [7845005.001]
  • [Cites] Am J Hum Genet. 1995 Apr;56(4):915-25 [7717402.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Feb;86(2):177-80 [8603351.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jun;95(2):213-4 [9169044.001]
  • [Cites] Am J Hematol. 1998 Aug;58(4):278-84 [9692390.001]
  • [Cites] Lancet. 2000 Jan 15;355(9199):165-9 [10675114.001]
  • (PMID = 19882758.001).
  • [ISSN] 1862-1783
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / HLA-DR Antigens; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 1.11.1.7 / Peroxidase
  • [Other-IDs] NLM/ PMC2772888
  •  go-up   go-down


22. Carral A, de la Rubia J, Martín G, Martínez J, Sanz G, Jarque I, Sempere A, Soler MA, Marty ML, Sanz MA: Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies. Bone Marrow Transplant; 2002 May;29(10):825-32
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies.
  • Factors influencing hematopoietic recovery (HR) after autologous blood stem cell transplantation (ABSCT) were analyzed in 73 patients with various non-myeloid malignancies (NMM), and in 58 patients with acute myeloblastic leukemia (AML).
  • Peripheral blood stem cells were collected following mobilization with chemotherapy, granulocyte colony-stimulating factor (G-CSF), or chemotherapy plus G-CSF.
  • The conditioning regimen used consisted of either chemotherapy alone (112 cases) or chemotherapy plus total body irradiation (19 cases).
  • The median number of colony-forming units granulocyte-macrophage (CFU-GM) was similar in both groups of patients, with the median number of CD34(+) cells infused being higher in the AML group (5.4 vs 4 x 10(6)/kg; P = 0.03).
  • Median time neutrophils >0.5 x 10(9)/l was 13 days in both groups, and median time to a platelet count >20 x 10(9)/l was longer in AML patients (14 vs 12 days; P = 0.01).
  • In multivariate analysis, the only factors affecting neutrophil recovery in the NMM group were the CD34+ cell number (continuous model) and the CFU-GM dose (categorized model) infused, whereas for platelet recovery, previous chemotherapy also remained significant.
  • In the AML group, the only factors significantly affecting the speed of neutrophil recovery were dose of CD34+ cells administered and the patient's age.
  • In the NMM group, the most discriminating cut-off values for a rapid neutrophil and platelet recovery were 1.5 x 10(6) and 2.5 x 10(6) CD34+ cells/kg, respectively, and for AML patients these figures were 1.5 x 10(6) and 4 x 10(6) CD34+ cells/kg, respectively.
  • Our results confirm the slower HR after ABSCT in AML, and highlight the importance of progenitor cell dose in accelerating HR after ABSCT.
  • [MeSH-major] Hematopoiesis. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Breast Neoplasms / pathology. Breast Neoplasms / therapy. Colony-Forming Units Assay. Female. Hodgkin Disease / pathology. Hodgkin Disease / therapy. Humans. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Multiple Myeloma / pathology. Multiple Myeloma / therapy. Transplantation, Autologous

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12058232.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Buyukhatipoglu H, Sevinc A, Camci C, Buyukberber S, Sari I: A case representing coexistence of acute myeloblastic leukemia and dedifferentiated liposarcoma: the possible role of chemotherapy in triggering dedifferentiation. Clin Lab Haematol; 2006 Oct;28(5):343-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case representing coexistence of acute myeloblastic leukemia and dedifferentiated liposarcoma: the possible role of chemotherapy in triggering dedifferentiation.
  • Acute myelogenous leukemia (AML) is a hematological disorder that is characterized by an abnormal proliferation of immature myeloid cells.
  • This process largely is believed to progress in a time-dependant manner; however, time is not the only factor of importance.
  • To date, the coexistence of AML and liposarcoma has not been reported in the literature.
  • In this paper, we report on a case of coexistence of AML and liposarcoma, and on the unusual behavior of a well-differentiated tumor after dedifferentiation occurs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / drug therapy. Liposarcoma / chemically induced

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16999727.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Blaise DP, Michel Boiron J, Faucher C, Mohty M, Bay JO, Bardoux VJ, Perreau V, Coso D, Pigneux A, Vey N: Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer; 2005 Nov 1;104(9):1931-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment.
  • BACKGROUND: Thirty-three patients (median age 52; range 26-60) with acute myeloblastic leukemia (AML) were included in a pilot study of allogeneic stem cell transplantation (Allo-SCT) following a reduced-intensity conditioning (RIC).
  • METHODS: Patients achieving first complete remission (CR1) were selected for their high-risk clinical and/or leukemic features.
  • All patients received two courses of consolidation chemotherapy including one high-dose cytarabine course.
  • RESULTS: All patients engrafted had cumulative incidences of Gluksberg System Grade 2 acute and chronic graft-versus-host-disease (GVHD) of 24 (9-39%) and 64 (48-80%), respectively.
  • With a median follow-up of 18 months (range 7-52) after Allo-SCT, 26 patients are alive, of whom 24 remained in CR1 for a 2-year overall survival and leukemia-free survival (LFS) probabilities of 79 (range 61-90%) and 76 (range 59-87%), respectively.
  • In a 'landmark' analysis starting on Day 100, the occurrence of chronic GVHD was associated with a lower relapse rate (0% vs. 44%: P = 0.007) and improved outcome (LFS; 95% vs. 53%, P = 0.007; overall survival, 95% vs. 61%, P = 0.05).
  • CONCLUSIONS: We conclude that the sequential combination of intensive chemotherapy and allogeneic immunotherapy might offer relatively low NRD and leukemia relapse rates even in high-risk patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / therapy. Stem Cell Transplantation / methods. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Pilot Projects. Remission Induction. Retrospective Studies. Survival Analysis. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 16178004.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Entz-Werle N, Suciu S, van der Werff ten Bosch J, Vilmer E, Bertrand Y, Benoit Y, Margueritte G, Plouvier E, Boutard P, Vandecruys E, Ferster A, Lutz P, Uyttebroeck A, Hoyoux C, Thyss A, Rialland X, Norton L, Pages MP, Philippe N, Otten J, Behar C, EORTC Children Leukemia Group: Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. Leukemia; 2005 Dec;19(12):2072-81
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report.
  • The first EORTC (European Organization of Research and Treatment of Cancer) acute myeloblastic leukemia (AML) pilot study (58872) was conducted between January 1988 and December 1991.
  • It indicated that mitoxantrone could be substituted for conventional anthracyclines in the treatment of childhood AML without inducing cardiotoxicity.
  • The aim of the next EORTC 58921 trial was to compare the efficacy and toxicity of idarubicin vs mitoxantrone in initial chemotherapy courses, further therapy consisting of allogeneic bone marrow transplantation (alloBMT) in patients with an HLA-compatible sibling donor or chemotherapy in patients without a donor.
  • In patients with or without a donor, the 7-year disease-free survival (DFS) rate was 63 (8) and 57% (5%) and the 7-year survival rate was 78 (7) and 65% (5%), respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Protocols / standards. Bone Marrow Transplantation. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Idarubicin / therapeutic use. Infant. Infant, Newborn. Male. Mitoxantrone / therapeutic use. Remission Induction. Survival Rate. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16136166.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10-CA11488-18; United States / NCI NIH HHS / CA / 5U10-CA11488-35
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] BZ114NVM5P / Mitoxantrone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


26. Dimicoli S, Fohlen-Walter A, Mansuy L, Buisine J, Grégoire MJ, Lecompte T, Bordigoni P, Jonveaux P, Lesesve JF: [Acute myeloblastic leukemia without maturation (AML-M1) with basophilic elements and associated with translocation t(6;9)]. Ann Biol Clin (Paris); 2003 May-Jun;61(3):352-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute myeloblastic leukemia without maturation (AML-M1) with basophilic elements and associated with translocation t(6;9)].
  • [Transliterated title] Leucémie aiguë myéloblastique sans maturation (LAM1) avec éléments basophiles associée à la translocation t(6;9).
  • The clinical, hematological, and cytogenetic data from a 4 year-old child with acute myeloid (AML-M1) and basophilia is reported.
  • This abnormality is rare and associated with myelodysplastic syndromes or with subtypes of acute myeloid leukemia (M1, M2, M4, M7), usually with preceding or underlying myelodysplasia.
  • The prognosis is poor, without response to chemotherapy regimen alone.
  • Allogeneic bone marrow transplantation appears likely to be a more appropriate treatment.
  • [MeSH-major] Basophils. Chromosomes, Human, Pair 6 / genetics. Chromosomes, Human, Pair 9 / genetics. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12805015.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Hemoglobins
  •  go-up   go-down


27. Li S, Zhang L, Kern WF, Andrade D, Forsberg JE, Bates FR, Mulvihill JJ: Identification of t(15;17) and a segmental duplication of chromosome 11q23 in a patient with acute myeloblastic leukemia M2. Cancer Genet Cytogenet; 2002 Oct 15;138(2):149-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of t(15;17) and a segmental duplication of chromosome 11q23 in a patient with acute myeloblastic leukemia M2.
  • A 32-year-old man was newly diagnosed with acute myelocytic leukemia, classified as acute myeloblastic leukemia with maturation (AML-M2) according to the French-American-British classification system.
  • Conventional chromosome analysis before chemotherapy treatment revealed an abnormal karyotype: a possible segmental duplication of 11q23, plus a translocation between chromosomes 15 and 17 [t(15;17) (q22;q21.1)] in the majority of cells analyzed.
  • To our knowledge, this is the first report of a combination of t(15;17) and a segmental duplication of 11q23 in a patient with AML-M2.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 15 / genetics. Chromosomes, Human, Pair 17 / genetics. Gene Duplication. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Chromosome 17, Duplication.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12505261.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Gutierrez-Aguirre CH, Cantú-Rodríguez OG, Gonzalez-Llano O, Salazar-Riojas R, Martinez-González O, Jaime-Pérez JC, Morales-Toquero A, Tarín-Arzaga LC, Ruiz-Argüelles GJ, Gómez-Almaguer D: Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. Hematology; 2007 Jun;12(3):193-7
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.
  • Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective strategy for preventing relapse of acute myelogenous leukemia (AML).
  • We analyzed the outcome of 31 primary AML patients who received a reduced-intensity conditioning regimen for allogeneic HSCT in first or second remission.
  • Thirty-one AML patients, 20 in first complete remission (FCR), 8 in second complete remission (SCR) and 3 in a partial remission (SPR) were included.
  • All patients received cyclosporine-A (CsA) and methotrexate as graft vs. host disease (GvHD) prophylaxis.
  • All patients showed myeloid engraftment (neutrophils >0.5 x 10(9)/l) after a median of 13 days in FCR group and 15 days in SCR group.
  • Conclusions. Reduced-intensity conditioning followed by allogeneic HSCT can induce stable remission in primary AML patients transplanted in FCR.
  • A high relapse rate was documented in patients with refractory or relapsed AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Busulfan / administration & dosage. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cyclosporine / administration & dosage. Graft Survival. Graft vs Host Disease / drug therapy. Graft vs Host Disease / prevention & control. Humans. Mexico. Middle Aged. Recurrence. Salvage Therapy / methods. Transplantation Conditioning / methods. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558694.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 83HN0GTJ6D / Cyclosporine; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  •  go-up   go-down


29. Woronoff-Lemsi MC, Witz F, Arveux P, Cahn JY, Harousseau JL, GOELAM Sa3 (Groupe Est d'etudes des Leucemies et Autres Maladies du Sang): [Cost effectiveness of GM-CSF in the treatment of acute myeloblastic leukemia in aged patients: protocol of GOELAM Sa3]. Therapie; 2001 Mar-Apr;56(2):131-3
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cost effectiveness of GM-CSF in the treatment of acute myeloblastic leukemia in aged patients: protocol of GOELAM Sa3].
  • [Transliterated title] Intérêt thérapeutique et économique du GM-CSF dans le traitement des leucémies aiguës myéloblastiques du sujet âgé: protocole GOELAM Sa3.
  • A cost-effectiveness analysis was carried out from a randomized placebo-controlled protocol of GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia (AML).
  • A total of 240 patients with de novo AML and aged 55 to 75 years were enrolled.
  • Overall survival and disease-free survival were analysed for efficacy within five years and expressed in gained life-years.
  • For disease free-survival, costs were FF 357,167 for placebo patients and FF 320,736 for GM-CSF patients.
  • For overall survival and disease free-survival the cost savings by GM-CSF were, respectively, FF 54,730 and FF 36,431.
  • [MeSH-major] Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Aged. Cost-Benefit Analysis. Disease-Free Survival. France. Humans. Middle Aged. Placebos. Recombinant Proteins. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11471363.001).
  • [ISSN] 0040-5957
  • [Journal-full-title] Thérapie
  • [ISO-abbreviation] Therapie
  • [Language] fre
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Placebos; 0 / Recombinant Proteins; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


30. Ghosh K, Mitra S, Hiwase D: Choroidal infiltrates simulating fundal changes of acute leukemia during hematological recovery following high-dose chemotherapy in acute myelomonocytic leukemia in remission. Am J Hematol; 2000 Jan;63(1):42-5
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroidal infiltrates simulating fundal changes of acute leukemia during hematological recovery following high-dose chemotherapy in acute myelomonocytic leukemia in remission.
  • A young female patient of 18 who was diagnosed to have acute myelomonocytic leukemia (AML M4) developed choroidal infiltrate and fundal changes suggestive of acute leukemia deposits while she was in remission and was recovering from chemotherapy induced myelosuppression.
  • The choroidal lesion resolved on its own in 2 week's time, when the peripheral and CSF monocytosis subsided.
  • [MeSH-major] Choroid / pathology. Leukemia, Myelomonocytic, Acute / drug therapy. Leukemia, Myelomonocytic, Acute / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cerebrospinal Fluid / cytology. Cytarabine / administration & dosage. Cytoplasmic Granules / pathology. Daunorubicin / administration & dosage. Female. Humans. Leukocyte Count. Mitoxantrone / administration & dosage. Monocytes / pathology. Remission Induction

  • Genetic Alliance. consumer health - Acute Myelomonocytic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10602168.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


31. Pamuk GE, Taşçi M, Oztürk E, Demir M: Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII : report on one case and review of other uses in acute leukemias. Med Oncol; 2010 Mar;27(1):16-9
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII : report on one case and review of other uses in acute leukemias.
  • Hemorrhage is a frequent complication in patients with acute leukemias as a result of chemotherapy-induced myelosuppression.
  • Patients are generally managed with red blood cell, platelet suspensions, and fresh frozen plasma; and sometimes with pharmacologic and endoscopic interventions.
  • If these therapeutic measures fail, patients might be treated with hemostatic drugs, one example of which is recombinant activated factor VII (rFVIIa).
  • This drug is recommended for all kinds of bleeding in hemophiliacs with inhibitors; it is also being used for the treatment of bleeding in thrombocytopenia and platelet function disorders.
  • We present our 44-year-old female patient who had gastrointestinal system bleeding after remission induction therapy for acute myeloid leukemia.
  • Our experience indicates that rFVIIa might be a novel treatment alternative in massive bleeding in leukemic patients with thrombocytopenia or platelet function disorders.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Factor VIIa / administration & dosage. Gastrointestinal Hemorrhage / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Recombinant Proteins / administration & dosage
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Female. Humans. Idarubicin / administration & dosage. Idarubicin / adverse effects. Injections, Intravenous. Remission Induction. Thrombocytopenia / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood Coagul Fibrinolysis. 2004 Apr;15(3):261-3 [15060424.001]
  • [Cites] Bone Marrow Transplant. 2007 Jun;39(12 ):729-35 [17417659.001]
  • [Cites] Semin Thromb Hemost. 2000;26(4):413-9 [11092217.001]
  • [Cites] Am J Hematol. 2005 Aug;79(4):344-5 [16044447.001]
  • [Cites] Gastroenterol Clin North Am. 2003 Dec;32(4):1053-78 [14696297.001]
  • [Cites] Bone Marrow Transplant. 2001 Aug;28(4):405-7 [11571515.001]
  • [Cites] Pediatr Blood Cancer. 2008 May;50(5):1013-7 [17960639.001]
  • [Cites] Arch Intern Med. 2000 Jul 24;160(14 ):2216-7 [10904466.001]
  • [Cites] Blood Coagul Fibrinolysis. 2005 Mar;16(2):145-7 [15741803.001]
  • [Cites] Br J Haematol. 2002 Jun;117(3):705-8 [12028045.001]
  • [Cites] Eur J Haematol. 2004 Jun;72 (6):455-6 [15128428.001]
  • [Cites] Gut. 2002 Oct;51 Suppl 4:iv1-6 [12208839.001]
  • [Cites] Blood Coagul Fibrinolysis. 2006 Jun;17(4):323-4 [16651877.001]
  • [Cites] Am J Gastroenterol. 1995 Apr;90(4):568-73 [7717312.001]
  • [Cites] Blood Coagul Fibrinolysis. 1998 Mar;9 Suppl 1:S61-5 [9819030.001]
  • [Cites] Haemostasis. 1996;26 Suppl 1:159-64 [8904193.001]
  • [Cites] Blood Coagul Fibrinolysis. 1998 Mar;9 Suppl 1:S15-20 [9819024.001]
  • [Cites] J Thromb Haemost. 2003 Mar;1(3):606-8 [12871480.001]
  • [Cites] BMJ. 2001 Nov 10;323(7321):1115-7 [11701581.001]
  • [Cites] Clin Lab Haematol. 2004 Jun;26(3):229-31 [15163323.001]
  • [Cites] Thromb J. 2006 Jan 18;4:1 [16420687.001]
  • [Cites] Eur J Haematol. 2007 Feb;78(2):173-4 [17313564.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 May;13(5):622-3 [17448923.001]
  • [Cites] Am J Hematol. 2006 Sep;81(9):720 [16804937.001]
  • [Cites] Br J Haematol. 1999 Jul;106(1):254-5 [10444198.001]
  • [Cites] Crit Care Med. 2005 Apr;33(4):883-90 [15818119.001]
  • [Cites] Blood Coagul Fibrinolysis. 2000 Apr;11 Suppl 1:S107-11 [10850574.001]
  • [Cites] Haemostasis. 1996;26 Suppl 1:143-9 [8904190.001]
  • [Cites] Pediatr Hematol Oncol. 2006 Jun;23 (4):339-45 [16621776.001]
  • [Cites] Bone Marrow Transplant. 2002 Dec;30(12):975-8 [12476294.001]
  • (PMID = 19137431.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; EC 3.4.21.21 / Factor VIIa; ZRP63D75JW / Idarubicin
  •  go-up   go-down


32. Bertozzi AI, Suc A, Rubie H, Duchayne E, Demur C, Robert A: [Hemophagocytic syndrome associated with neutropenia after chemotherapy]. Arch Pediatr; 2002 Feb;9(2):125-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hemophagocytic syndrome associated with neutropenia after chemotherapy].
  • RESULTS: Underlying diseases were acute lymphoblastic leukemia (n = 8) acute myeloblastic leukemia (n = 6) and Burkitt lymphoma (n = 1).
  • Hemophagocytic syndrome was suspected after chemotherapy, in case of an unusual prolonged febrile neutropenia (n = 14) or isolated thrombocytopenia (n = 1).
  • Diagnosis of hemophagocytic syndrome was always confirmed by bone marrow aspiration (infiltration with activated macrophages).
  • The treatment of hemophagocytic syndrome relied on steroids and resolution of symptoms occurred within three days of therapy.
  • No recurrence of hemophagocytic syndrome was observed with a median follow up of two years and a half.
  • Indeed, steroid therapy is effective and chemotherapy can be then pursued.
  • [MeSH-minor] Adrenal Cortex Hormones / administration & dosage. Adrenal Cortex Hormones / therapeutic use. Age Factors. Burkitt Lymphoma / drug therapy. Child. Child, Preschool. Female. Humans. Infant. Leukemia, Myeloid, Acute / drug therapy. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Retrospective Studies. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11915492.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


33. Allan DS, Buckstein R, Imrie KR: Outpatient supportive care following chemotherapy for acute myeloblastic leukemia. Leuk Lymphoma; 2001 Jul;42(3):339-46
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient supportive care following chemotherapy for acute myeloblastic leukemia.
  • Treatment of acute myeloid leukemia (AML) involves aggressive myelosuppressive chemotherapy that is generally administered on an inpatient basis.
  • In our centre, AML therapy has been initiated in hospital and followed by early outpatient supportive care according to guidelines established in 1996.
  • We conducted a review of all patients presenting with AML in our centre between January 1996 and July 1998 to evaluate the safety and feasibility of early outpatient supportive care.
  • Nineteen consecutive patients treated with induction chemotherapy were analyzed.
  • Patients were treated with cytosine arabinoside and an anthracycline as aggressive AML induction therapy with the intent for early discharge.
  • Ten patients (53%) were discharged within 10 days of starting induction chemotherapy (median 4.5 days).
  • Patients discharged early had a median of 1.5 readmissions (range 0-3), but had 30% fewer in-hospital days than inpatients (p = 0.03), and 57% fewer days of in-hospital antibiotic therapy (p = 0.01).
  • Thirty-one cycles of consolidation therapy were administered to the 18 patients who survived induction.
  • Nine cycles of consolidation chemotherapy were delivered using outpatient intravenous infusion pumps (29%).
  • This study supports the feasibility and safety of early discharge and outpatient supportive care following chemotherapy for AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Outpatients. Patient Discharge. Social Support
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antibiotics, Antineoplastic / administration & dosage. Cytarabine / administration & dosage. Feasibility Studies. Female. Growth Substances / therapeutic use. Humans. Inpatients. Male. Middle Aged. Patient Readmission / statistics & numerical data. Remission Induction. Retrospective Studies. Safety. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11699398.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Growth Substances; 04079A1RDZ / Cytarabine
  •  go-up   go-down


34. Hiçsönmez G, Cetin M, Tuncer AM, Yenicesu I, Aslan D, Ozyürek E, Unal S: Children with acute myeloblastic leukemia presenting with extramedullary infiltration: the effects of high-dose steroid treatment. Leuk Res; 2004 Jan;28(1):25-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Children with acute myeloblastic leukemia presenting with extramedullary infiltration: the effects of high-dose steroid treatment.
  • To evaluate whether children with acute myeloblastic leukemia (AML) presenting with extramedullary infiltration (EMI) have different clinical, morphologic features and prognosis from children without EMI, a 127 consecutive previously untreated children with AML were entered in this study.
  • Fifty-one children (40%) had EMI at diagnosis and 27% of these showed multiple site involvement.
  • Twenty-seven of 127 children (21%) presented myeloid tumors.
  • However, analysis of clinical and biological features at diagnosis showed that WBC count > or =50 x 10(9) l(-1), hepatosplenomegaly >5 cm, FAB AML-M4 and AML-M5 subtypes and CD13, CD14 expression of bone marrow (BM) leukemic cells (>20%) were more frequent in children with EMI.
  • Two consecutive treatment protocols were used.
  • In both protocols remission was achieved with combined high-dose methylprednisolone (HDMP) as a differentiating and apoptosis inducing agent with mild cytotoxic chemotherapy (low-dose cytosine arabinoside (LD Ara-C), weekly mitoxantrone and Ara-C or 6-thioguanine).
  • However, in patients who presented with myeloblastoma and treated with a more intensive post-remission therapy (AML-94), the 4-year disease-free survival (DFS) and event-free survival (EFS) rates were not found to be significantly different from children who had no EMI (P>0.05).
  • In further studies, the prognostic significance of different localisation of EMI and the effect of addition of HDMP to cytotoxic chemotherapy should be explored in larger series.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / diagnosis. Leukemic Infiltration / diagnosis
  • [MeSH-minor] Acute Disease. Antigens, CD13 / metabolism. Antigens, CD14 / metabolism. Blast Crisis. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. Child. Child, Preschool. Cytarabine / administration & dosage. Female. Humans. Male. Methylprednisolone / administration & dosage. Mitoxantrone / administration & dosage. Prognosis. Remission Induction. Survival Rate. Thioguanine / administration & dosage. Treatment Outcome

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14630077.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD14; 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone; EC 3.4.11.2 / Antigens, CD13; FTK8U1GZNX / Thioguanine; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


35. Tóthová E, Stecová N, Kafková A, Fricová M, Guman T, Elbertová A: [Relation between Bcl-2 protein expression and results of therapy in patients with acute myeloblastic leukemia]. Vnitr Lek; 2004 Feb;50(2):139-42
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relation between Bcl-2 protein expression and results of therapy in patients with acute myeloblastic leukemia].
  • Flow cytometric expression of Bcl-2 protein was analyzed in 67 newly diagnosed acute myeloblastic leukemia (AML) patients using an anti-Bcl-2 monoclonal antibody by direct immunofluorescence technique and result were correlated with FAB subtype, CD34 expression and clinical outcome.
  • The percentage of Bcl-2+ cells was higher in M0 and M1 types according French-American-British classification.
  • The mean fluorescence index (MFI), expressed as the ratio of sample channel: control mean channel was significantly higher (p < 0.01) in M0 (19.0) and M1 (17.6) than M4 (11.7) and M5 (8.9) cytotypes.
  • High percentage expression of Bcl-2 and MFI index of Bcl 2 was associated with a low complete remission rate after intensive chemotherapy (40.4% in cases with 20% and more positive cells vs 72% in cases with less than 20% positive cells).
  • By statistical analysis we also demonstrated that both Bcl-2 high MFI (> 16) and CD34 expression are independent prognostic factors for achieving CR in AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Proto-Oncogene Proteins c-bcl-2 / analysis
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / analysis. Female. Fluorescent Antibody Technique, Direct. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15077589.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] slo
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


36. Sarper N, Ozbek U, Ağaoğlu L, Ozgen U, Eryilmaz E, Yalman N, Anak S, Devecioğlu O, Gedikoğlu G: Is AML1/ETO gene expression a good prognostic factor in pediatric acute myeloblastic leukemia? Pediatr Hematol Oncol; 2000 Oct-Nov;17(7):577-83
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is AML1/ETO gene expression a good prognostic factor in pediatric acute myeloblastic leukemia?
  • To assess the clinical significance of AML1/ETO gene detected by nested reverse transcriptase polymerase chain reaction, the outcome of 7 patients with acute myeloblastic leukemia between 3 and 14 years of age were presented.
  • All patients had complete remission (CR) at the end of induction (AML-MRC 10 protocol) and 4 underwent unpurged autologous, 2 allogeneic (from matched siblings) non-T-cell-depleted bone marrow transplantations (BMT) in first CR.
  • All relapsed patients died between 18 and 36 months with resistant disease (n = 3) or infection during salvage chemotherapy (n = 1).
  • Two patients who had autologous BMT are alive and disease free at 44 and 50 months.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adolescent. Bone Marrow Transplantation. Child. Child, Preschool. Combined Modality Therapy. Core Binding Factor Alpha 2 Subunit. Disease-Free Survival. Female. Gene Expression. Humans. Leukemia, Monocytic, Acute / genetics. Leukemia, Monocytic, Acute / metabolism. Leukemia, Monocytic, Acute / therapy. Leukemia, Myelomonocytic, Acute / genetics. Leukemia, Myelomonocytic, Acute / metabolism. Leukemia, Myelomonocytic, Acute / therapy. Leukemia, Promyelocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / metabolism. Leukemia, Promyelocytic, Acute / therapy. Male. RNA, Messenger / analysis. RNA, Messenger / genetics. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11033733.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / Transcription Factors
  •  go-up   go-down


37. Pulsoni A, Iacobelli S, Bernardi M, Borgia M, Camera A, Cantore N, Di Raimondo F, Fazi P, Ferrara F, Leoni F, Liso V, Mancini M, Marmont F, Matturro A, Maurillo L, Melillo L, Meloni G, Mirto S, Specchia G, Valentini CG, Venditti A, Leone G, Foà R, Mandelli F, Pagano L: M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. Haematologica; 2008 Jul;93(7):1025-32
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience.
  • BACKGROUND: Myelomonocytic acute myeloid leukemia (M4-AML) is frequently associated with the cytogenetic marker inv(16) and/or the presence of eosinophilia.
  • DESIGN AND METHODS: Adult patients with acute myeloid leukemia consecutively enrolled in the GIMEMA trials AML10 and LAM99p were retrospectively analyzed.
  • RESULTS: Among 1686 patients, 400 cases of M4-AML were identified; of these, 78% had neither eosinophilia nor inv(16), 6% had eosinophilia only, 8% had inv(16) only and 8% had both.
  • Univariate analysis showed that both eosinophilia and inv(16) were correlated with a higher probability of complete remission, lower resistance to chemotherapy and increased overall survival.
  • CONCLUSIONS: In a large series of patients with M4-AML we confirmed the favorable role of inv(16), but the weight of this factor among the whole M4 population was of limited relevance.
  • Based on the results of this large case population, overall and relapse-free survival rates of patients with M4-AML are not significantly better than those of patients with non-M4 AML, while the concomitant presence of both inv(16) and eosinophilia was associated with a significantly improved prognosis.
  • [MeSH-major] Cytogenetics / methods. Leukemia, Myelomonocytic, Acute / genetics. Leukemia, Myelomonocytic, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Chromosome Inversion. Combined Modality Therapy. Disease-Free Survival. Eosinophilia / diagnosis. Eosinophilia / genetics. Humans. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18508801.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] Italy
  •  go-up   go-down


38. De Braekeleer E, Douet-Guilbert N, Le Bris MJ, Morel F, Férec C, De Braekeleer M: RUNX1-MTG16 fusion gene in acute myeloblastic leukemia with t(16;21)(q24;q22): case report and review of the literature. Cancer Genet Cytogenet; 2008 Aug;185(1):47-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RUNX1-MTG16 fusion gene in acute myeloblastic leukemia with t(16;21)(q24;q22): case report and review of the literature.
  • A diagnosis of acute myeloid leukemia (AML) type 2 (FAB classification) was made.
  • The t(16;21)(q24;q22) has been described in 16 AML cases, including ours.
  • Eleven patients had received chemotherapy for a previous cancer, most of them were been treated with DNA-topoisomerase II inhibitors known to be associated with chromosomal translocations involving the RUNX1 gene.
  • [MeSH-major] Chromosomes, Human, Pair 16. Chromosomes, Human, Pair 21. Core Binding Factor Alpha 2 Subunit / genetics. Leukemia, Myeloid, Acute / genetics. Phosphoproteins / genetics. Repressor Proteins / genetics. Translocation, Genetic. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656694.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CBFA2T3 protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / Phosphoproteins; 0 / RUNX1 protein, human; 0 / Repressor Proteins; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 22
  •  go-up   go-down


39. Gähler A, Hitz F, Hess U, Cerny T: Acute pericarditis and pleural effusion complicating cytarabine chemotherapy. Onkologie; 2003 Aug;26(4):348-50
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute pericarditis and pleural effusion complicating cytarabine chemotherapy.
  • BACKGROUND: Pericarditis is a rare but possibly severe complication of treatment of acute leukemia with cytarabine.
  • CASE REPORT: We report a possibly cytarabine-induced acute pericarditis and pleuritis with a rapid onset.
  • A patient with acute myelomonocytic leukemia developed an isolated pericarditis 3 weeks after the first course of chemotherapy with cytarabine and idarubicin.
  • The second course of chemotherapy with cytarabine and amsacrine was started after clinical improvement; 3 days later an acute pericarditis with a large pericardial effusion accompanied by a left pleural effusion developed.
  • The third course of chemotherapy with mitoxantrone and etoposide was completed without further cardiopulmonary complications.
  • CONCLUSION: The differential diagnosis of pericarditis in the setting of chemotherapy with cytarabine should include cytarabine- induced pericarditis.
  • Severe progression with massive pericardial effusion necessitating risky pericardiocentesis can occur and therefore a therapy with high-dose corticosteroids should be considered early.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cytarabine / adverse effects. Leukemia, Myelomonocytic, Acute / drug therapy. Pericarditis / chemically induced. Pleural Effusion / chemically induced
  • [MeSH-minor] Acute Disease. Humans. Male. Middle Aged. Recurrence

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger GmbH, Freiburg
  • (PMID = 12972701.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


40. Tasaka T, Nagai M, Matsuhashi Y, Uehara E, Kakazu N, Abe T, Tamura T: Marked thrombocytosis following relapse of acute myeloblastic leukemia associated with development of translocation (2;14) (p13;q32). Leuk Lymphoma; 2002 Oct;43(10):2063-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marked thrombocytosis following relapse of acute myeloblastic leukemia associated with development of translocation (2;14) (p13;q32).
  • Thrombocytosis is a rare finding in acute myeloblastic leukemia (AML).
  • Here, we describe a patient with AML who relapsed with marked thrombocytosis.
  • The patient was initially diagnosed as having AML (M4) with a low platelet count.
  • The patient was started on combination chemotherapy including high-dose etoposide and achieved complete remission.
  • Despite the repeated combination chemotherapy, the patient died with progressive disease.
  • This case suggests that the additional chromosomal aberration t(2;14)(p13;q32) may be related to abnormal thrombocytosis in AML.
  • [MeSH-major] Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 2. Leukemia, Myelomonocytic, Acute / complications. Thrombocytosis / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Cytogenetic Analysis. Disease Progression. Fatal Outcome. Humans. Male. Platelet Count. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12481911.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


41. Tóthová E, Fricova M, Stecová N, Kafková A, Elbertová A: High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Neoplasma; 2002;49(3):141-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy.
  • Flow cytometric expression of bcl-2 protein was analyzed in 67 newly diagnosed acute myeloblastic leukemia (AML) patients using an anti-bcl-2 monoclonal antibody by direct immunofluorescence technique and results were correlated with FAB subtype, CD34 expression and clinical outcome.
  • The number of bcl-2+ cells in each sample was heterogenous (range, 19% to 96%), with a mean of 81%.
  • The percentage of bcl-2+ cells was higher in M0 and M1 types according to French-American-British classification.
  • The mean fluorescence index (MFI), expressed as the ratio of sample channel:control mean channel was significantly higher (p=0.01) in M0 (19.0) and M1 (17.6) than M4 (11.7) and M5 (8.9) cytotypes.
  • High percentage expression of bcl-2 and MFI index of bcl-2 was associated with a low complete remission rate after intensive chemotherapy (40.4% in cases with 20% and more positive cells vs 72% in cases with less than 20% positive cells).
  • By statistical analysis we also demonstrated that both bcl-2 high MFI (>16) and CD34 expression are independent prognostic factors for achieving CR in AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Proto-Oncogene Proteins c-bcl-2 / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD34 / analysis. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12097997.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


42. Lester WA, Hull DR, Fegan CD, Morris TC: Respiratory failure during induction chemotherapy for acute myelomonocytic leukaemia (FAB M4Eo) with ara-C and all-trans retinoic acid. Br J Haematol; 2000 Jun;109(4):847-50
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Respiratory failure during induction chemotherapy for acute myelomonocytic leukaemia (FAB M4Eo) with ara-C and all-trans retinoic acid.
  • We report two cases of acute myeloid leukaemia FAB classification M4Eo with high white cell counts at presentation, who developed acute respiratory failure with pulmonary infiltrates on chest radiograph soon after commencing conventional cytotoxic chemotherapy plus all-trans retinoic acid (ATRA).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myelomonocytic, Acute / complications. Leukemia, Myelomonocytic, Acute / drug therapy. Respiratory Insufficiency / etiology. Tretinoin / therapeutic use
  • [MeSH-minor] Adult. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Dexamethasone / therapeutic use. Female. Glucocorticoids / therapeutic use. Humans. Remission Induction. Thioguanine / administration & dosage

  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10929040.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Glucocorticoids; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; 7S5I7G3JQL / Dexamethasone; FTK8U1GZNX / Thioguanine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


43. Sepúlveda E, Brethauer U, Rojas J, Fernández E, Le Fort P: Oral ulcers in children under chemotherapy: clinical characteristics and their relation with Herpes Simplex Virus type 1 and Candida albicans. Med Oral Patol Oral Cir Bucal; 2005;10 Suppl 1:E1-8
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral ulcers in children under chemotherapy: clinical characteristics and their relation with Herpes Simplex Virus type 1 and Candida albicans.
  • OBJECTIVE: The objective of this study was to determine the clinical characteristics of oral ulcers in pediatric oncology patients undergoing chemotherapy and their relation with the presence of Herpes Simplex Virus (HSV) type 1 and Candida albicans.
  • STUDY DESIGN: The sample consisted of 20 ulcerative lesions from 15 children treated with chemotherapy in the Pediatric Service of the Regional Hospital of Concepción, Chile.
  • Two calibrated clinicians performed clinical diagnosis of the ulcers and registered general data from the patients (age, general diagnosis, absolute neutrophil count, and number of days after chemotherapy) and clinical characteristic of the ulcers: number, size, location, presence or absence of pain and inflammatory halo, edge characteristics, and exudate type.
  • Additional to clinical diagnosis, culture for Candida albicans (C) and polymerase chain reaction (PCR) for Herpes Simplex Virus type 1 was performed.
  • RESULTS: Ten ulcers occurred in patients with acute lymphoblastic leukemia, five in patients with acute myeloblastic leukemia and five in patients with other neoplastic diseases.
  • The average size was 6,5 millimeters, and the mean number of days after chemotherapy was 7.5 days.
  • CONCLUSIONS: Oral ulcers in children with oncological diseases did not present a specific clinical pattern.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Herpesvirus 1, Human / pathogenicity. Leukemia / drug therapy. Oral Ulcer / virology. Stomatitis, Herpetic / etiology

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800462.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Viral
  •  go-up   go-down


44. Kawasaki H, Isoyama K, Eguchi M, Hibi S, Kinukawa N, Kosaka Y, Oda T, Oda M, Nishimura S, Imaizumi M, Okamura T, Hongo T, Okawa H, Mizutani S, Hayashi Y, Tsukimoto I, Kamada N, Ishii E: Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group. Blood; 2001 Dec 15;98(13):3589-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group.
  • This study analyzed data on 35 infants with acute myeloid leukemia (AML) who were treated with intensive chemotherapy between 1995 and 1998 in Japan.
  • The incidence of boys, younger age (< 6 months old), and hyperleukocytosis at onset was high in patients with the M4/M5 subtype (n = 23) in the French-American-British classification, compared with the non-M4/M5 subtype (n = 12).
  • Thirteen (56%) and 16 (70%) patients with the M4/M5 subtype also showed 11q23 translocations and MLL gene rearrangements, respectively, whereas only one patient with the non-M4/M5 subtype had this rearrangement.
  • EFS showed no significant difference between 2 subgroups divided by age, gender, presence of the MLL gene rearrangements, and white blood cell count at onset; EFS in patients with the M4/M5 subtype tended to be better than those with the non-M4/M5 subtype.
  • These findings suggest that the intensive chemotherapy with the ANLL91 protocol might have been responsible for the observed good outcome of infant AML, even without SCT.
  • The presence of the MLL gene rearrangements or the age at onset had no impact on the outcome of infant AML.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Leukemia, Myeloid, Acute / drug therapy. Proto-Oncogenes. Transcription Factors. Treatment Outcome
  • [MeSH-minor] Aclarubicin / administration & dosage. Chromosomes, Human, Pair 11. DNA-Binding Proteins / genetics. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Female. Hematopoietic Stem Cell Transplantation. Histone-Lysine N-Methyltransferase. Humans. Immunophenotyping. Infant. Male. Mitoxantrone / administration & dosage. Myeloid-Lymphoid Leukemia Protein. Prognosis. Remission Induction. Survival Rate. Translocation, Genetic. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2002 Apr 1;99(7):2626-7 [11926186.001]
  • (PMID = 11739161.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Transcription Factors; 04079A1RDZ / Cytarabine; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 74KXF8I502 / Aclarubicin; 80168379AG / Doxorubicin; BZ114NVM5P / Mitoxantrone; D58G680W0G / pirarubicin; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; ANLL91 protocol
  •  go-up   go-down


45. Steinherz PG, Shukla N, Kobos R, Steinherz L: Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. Pediatr Blood Cancer; 2010 May;54(5):687-93
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
  • BACKGROUND: We determined the maximum tolerated dose (MTD) of clofarabine when administered with topotecan, vinorelbine, thiotepa, and dexamethasone (TVTC) for children with relapsed or refractory acute leukemia, and observed the efficacy and toxicities of this therapy.
  • PROCEDURE: Twelve patients with acute lymphoblastic or myeloblastic leukemia were given a 14-day remission induction therapy.
  • Three patients had progressive disease.
  • One patient died on day 45 with marrow hypoplasia without evidence of leukemia.
  • CONCLUSION: TVTC has significant anti-leukemic activity in both acute lymphoblastic and myeloblastic leukemia.
  • This is the recommended dose for the phase II study in patients with refractory or relapsed leukemia, a population which has limited therapeutic options.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy
  • [MeSH-minor] Adenine Nucleotides / administration & dosage. Adenine Nucleotides / adverse effects. Adolescent. Adult. Arabinonucleosides / administration & dosage. Arabinonucleosides / adverse effects. Child. Child, Preschool. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Hematopoietic Stem Cell Transplantation. Humans. Infant. Male. Maximum Tolerated Dose. Recurrence. Remission Induction. Thiotepa / administration & dosage. Thiotepa / adverse effects. Topotecan / administration & dosage. Topotecan / adverse effects. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205253.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 5V9KLZ54CY / Vinblastine; 762RDY0Y2H / clofarabine; 7M7YKX2N15 / Topotecan; 905Z5W3GKH / Thiotepa; Q6C979R91Y / vinorelbine
  •  go-up   go-down


46. Hvid K, Rosenborg D: [Hickman catheters for chemotherapy in patients with acute myeloblastic leukemia]. Ugeskr Laeger; 2005 Nov 28;167(48):4566-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hickman catheters for chemotherapy in patients with acute myeloblastic leukemia].
  • [Transliterated title] Hickman-katetre til kemoterapeutisk behandling af patienter med akut myeloblastaer leukaemi.
  • Permanent venous catheters are part of the treatment of haematology patients.
  • The rate of premature removal was 1.94 per 1,000 catheter days, and the infection rate was 1.04 per 1,000 catheter days.
  • [MeSH-major] Catheterization, Central Venous. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Bacterial Infections / etiology. Catheters, Indwelling / adverse effects. Equipment Contamination. Female. Humans. Male. Middle Aged. Prospective Studies. Sex Factors. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324439.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


47. Ginsberg JP, Orudjev E, Bunin N, Felix CA, Lange BJ: Isolated extramedullary relapse in acute myeloid leukemia: A retrospective analysis. Med Pediatr Oncol; 2002 Jun;38(6):387-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated extramedullary relapse in acute myeloid leukemia: A retrospective analysis.
  • BACKGROUND: Little is known about the characteristics and outcome of children with acute myeloid leukemia (AML) experiencing an isolated extramedullary relapse (IEMR).
  • PROCEDURE: The tumor registry of The Children's Hospital of Philadelphia identified 215 patients with AML diagnosed between 1970 and 2000, of which 16 (7.4%) experienced IEMR.
  • Patient- and disease-related features and outcome of patients with IEMR and other patients with AML were compared.
  • RESULTS: IEMR occurred a median of 4.5 months (1.5-74 months) from diagnosis.
  • Male to female ratio was 4.3:1 in patients with IEMR and 1.1:1 in the other patients with AML (P = 0.048).
  • Median age at diagnosis and median presenting WBC were not significantly different in patients with and without IEMR.
  • Patients with IEMR were more likely to have extramedullary disease (EMD) at diagnosis (31 vs. 4.5%) (P =.002) and FAB M4 or M5 morphology (P =.0001).
  • One survivor of IEMR received local irradiation and continued on maintenance therapy while the other five received chemotherapy, irradiation, and allogeneic marrow transplant in second or third remission.
  • CONCLUSIONS: Patients with isolated EMR are typically young males with monoblastic or myeloblastic leukemia who present with EMD at diagnosis.
  • Marrow transplant following chemotherapy and local radiotherapy offer the potential for long-term survival.
  • [MeSH-major] Leukemia, Myeloid / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Recurrence. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 11984798.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K12-CA76931; United States / NCI NIH HHS / CA / T32-CA09615
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


48. Numakura K, Tsuchiya N, Habuchi T, Takahashi N: [Therapy related leukemia with 11q23 abnormality induced by chemotherapy consisted of docetaxel for advanced prostatic carcinoma: case report]. Nihon Hinyokika Gakkai Zasshi; 2009 Jul;100(5):580-5
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy related leukemia with 11q23 abnormality induced by chemotherapy consisted of docetaxel for advanced prostatic carcinoma: case report].
  • A balanced translocation involving 11q23 (MLL gene) could be observed in therapy related leukemia (TRL) patients generally treated with topoisomerase II inhibitors.
  • Herein, we report a patient who developed acute myelomonocytic leukemia (AMMoL) with t (9;. 11) (p22;.
  • q23) following chemotherapy mainly consisted of docetaxel for advanced prostatic carcinoma.
  • A 69-year-old man was treated with a systemic chemotherapy containing docetaxel (total dose = 585 mg) for hormone-refractory metastatic poorly differentiated prostate carcinoma.
  • Although, no disease progression of the prostatic carcinoma was observed, AMMoL with t (9;. 11) (p22;.
  • q23) developed only ten months later from the administration of docetaxel.
  • q23) translocation and clinical course.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma / therapy. Chromosomes, Human, Pair 11 / genetics. Leukemia, Myelomonocytic, Acute / chemically induced. Leukemia, Myelomonocytic, Acute / genetics. Neoplasms, Second Primary. Prostatic Neoplasms / therapy. Taxoids / adverse effects. Translocation, Genetic
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Neoplasm Recurrence, Local / drug therapy. Prostatectomy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19663246.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel
  • [Number-of-references] 23
  •  go-up   go-down


49. Binder C, Tiemann M, Haase D, Humpe A, Kneba M: Isolated meningeal chloroma (granulocytic sarcoma)--a case report and review of the literature. Ann Hematol; 2000 Aug;79(8):459-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated meningeal chloroma (granulocytic sarcoma)--a case report and review of the literature.
  • Isolated chloromas (granulocytic sarcomas) are rare tumors, most of them progressing to acute myeloblastic leukemia within months.
  • There are still no conclusive treatment strategies for this entity; however, early antileukemic chemotherapy seems to lower the probability of developing systemic disease and prolong survival.
  • Two cycles of antileukemic induction chemotherapy were administered, followed by local irradiation and intensified consolidation therapy with autologous stem cell transplantation.
  • [MeSH-major] Leukemia, Myeloid / therapy. Meningeal Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Drug Therapy. Hematopoietic Stem Cell Transplantation. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10985368.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] GERMANY
  • [Number-of-references] 40
  •  go-up   go-down


50. Kröger N, Damon L, Zander AR, Wandt H, Derigs G, Ferrante P, Demirer T, Rosti G, Solid Tumor Working Party of the European Group for Blood and Marrow Transplantation, German Adjuvant Breast Cancer Study Group, University of California, San Francisco: Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. Bone Marrow Transplant; 2003 Dec;32(12):1153-7
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
  • The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy.
  • After a median follow-up of 57 months (range 10-125), three cases of secondary AML (sAML) were observed, resulting in a cumulative incidence of 0.94%.
  • One case of sAML developed 18 months after HDCT (FAB M3) The karyotype was translocation 15;17 and, after induction therapy, the patient underwent autologous stem cell transplantation, and is in complete remission (CR) of both breast cancer and AML.
  • The second patient developed AML (FAB M4eo with inversion 16) 5 months after HDCT.
  • This patient achieved CR after induction therapy, but died of infectious complication.
  • A third patient developed AML (FAB M4) 6 months after HDCT.
  • She achieved CR after induction therapy, but relapsed and expired 28 months after diagnosis of AML. sAML after mitoxantrone-based HDCT is a possible, but rare complication in breast cancer patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Leukemia, Myeloid / chemically induced. Mitoxantrone / adverse effects. Neoplasms, Second Primary / chemically induced
  • [MeSH-minor] Acute Disease. Adult. Aged. Bone Marrow Transplantation. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Doxorubicin / administration & dosage. Epirubicin / administration & dosage. Female. Humans. Incidence. Leukemia, Myelomonocytic, Acute / chemically induced. Leukemia, Promyelocytic, Acute / chemically induced. Leukemia, Radiation-Induced / epidemiology. Leukemia, Radiation-Induced / etiology. Lymphatic Metastasis. Melphalan / administration & dosage. Middle Aged. Paclitaxel / administration & dosage. Peripheral Blood Stem Cell Transplantation. Radiotherapy, Adjuvant / adverse effects. Thiotepa / administration & dosage. Transplantation Conditioning. Transplantation, Autologous

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14647269.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Review
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 3Z8479ZZ5X / Epirubicin; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 905Z5W3GKH / Thiotepa; BZ114NVM5P / Mitoxantrone; P88XT4IS4D / Paclitaxel; Q41OR9510P / Melphalan; ZS7284E0ZP / Daunorubicin
  • [Number-of-references] 35
  •  go-up   go-down


51. Wuchter C, Leonid K, Ruppert V, Schrappe M, Büchner T, Schoch C, Haferlach T, Harbott J, Ratei R, Dörken B, Ludwig WD: Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica; 2000 Jul;85(7):711-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
  • BACKGROUND AND OBJECTIVES: A multidrug-resistance (MDR) phenotype mediated by P-glycoprotein (P-gp) contributes to chemotherapy failure in acute leukemia.
  • However, the exact prognostic significance of this resistance mechanism is still unclear, mostly due to methodologic problems in P-gp detection.
  • We therefore investigated, whether P-gp expression levels or functional P-gp activity better predict response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
  • DESIGN AND METHODS: We examined cell samples of 121 adults with de novo acute myeloid leukemia (AML) and 102 children with newly diagnosed acute lymphoblastic leukemia (ALL) for P-gp expression and functional P-gp activity by flow cytometry.
  • P-gp function was determined by the rhodamine 123 (rh123)-efflux test (AML n=121, ALL n=102) and P-gp expression levels using the P-gp specific monoclonal antibodies (moabs) MRK-16 (AML n=51, ALL n=31), 4.E3 (AML n=35, ALL n=32), or UIC-2 (AML n=68, ALL n=50).
  • We correlated our findings with the immunophenotype, FAB morphology, cytogenetics and clinical data of the examined patients.
  • RESULTS: P-gp expression levels as detected by MRK-16 and 4.E3 were very low and did not differ between AML and ALL as estimated using relative fluorescence intensity (RFI) values and D-values by Kolmogorow-Smirnov (KS) statistics.
  • For moab UIC-2, P-gp expression levels were higher in AML than in ALL.
  • Within AML, moab UIC-2 mainly reacted with myelomonocytic-differentiated leukemic cells of the FAB M4/5 subtypes.
  • No correlation between P-gp expression levels as detected by MRK-16, 4.E3 or UIC-2 and the response to induction chemotherapy or relapse rate, both in AML and ALL, was observed.
  • However, a prognostic impact of P-gp expression levels on overall survival in AML was seen for moab MRK-16.
  • Moreover, within AML, P-gp function was higher in immature blast cells as defined by immunophenotype and FAB morphology and correlated with response to induction chemotherapy, relapse rate, overall survival as well as cytogenetic risk groups.
  • In ALL, the overall functional P-gp activity was lower than in AML and did not correlate with immunophenotypical subgroups, response to induction chemotherapy, relapse rate or overall survival.
  • INTERPRETATION AND CONCLUSIONS: Our data demonstrate a prognostic impact of P-gp in AML but not ALL and indicate that the functional rh123-efflux assay should be preferred for flow-cytometric P-gp evaluation in acute leukemia compared with P-gp expression analysis by monoclonal antibodies.
  • [MeSH-major] Drug Resistance, Multiple / genetics. Leukemia / drug therapy. P-Glycoprotein / genetics. P-Glycoprotein / physiology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. Child. Child, Preschool. Gene Expression. Humans. Infant. Infant, Newborn. Leukemia, Myeloid / drug therapy. Middle Aged. Phenotype. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prognosis. Recurrence. Survival Rate

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10897123.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0 / P-Glycoprotein
  •  go-up   go-down


52. Kara IO, Sahin B, Paydas S, Kara B: Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone. Leuk Lymphoma; 2005 Jul;46(7):1081-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone.
  • We present a case of granulocytic sarcoma (GS) of the heart.
  • A 28-year-old man with relapsed acute myelogenous leukemia (AML-M2) had undergone a non-myeloablative allogeneic peripheral stem cell transplantation.
  • Three years following transplantation, masses were evidenced in his heart by echocardiography but had completely disappeared following a common chemotherapy etoposide, mitoxantrone, ara-C (EMA) regimen for relapsed AML.
  • The involvement of the heart with GS is very rare and this is the first case of extramedullary disease in the heart after allogeneic transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / therapy. Peripheral Blood Stem Cell Transplantation / adverse effects. Sarcoma, Myeloid / drug therapy. Sarcoma, Myeloid / etiology
  • [MeSH-minor] Adult. Cytarabine / administration & dosage. Etoposide / administration & dosage. Heart Neoplasms / diagnosis. Heart Neoplasms / drug therapy. Heart Neoplasms / etiology. Humans. Male. Mitoxantrone / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Remission Induction. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019562.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


53. Heller A, Trifonov V, Rubtsov N, Sauerbrey A, Starke H, Loncarevic IF, Claussen U, Liehr T: Complex chromosomal rearrangements in a secondary acute myeloblastic leukemia after chemotherapy in TRAPS. Oncol Rep; 2003 Nov-Dec;10(6):1789-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex chromosomal rearrangements in a secondary acute myeloblastic leukemia after chemotherapy in TRAPS.
  • We report on the cytogenetic findings from a patient with a de novo TNF-receptor-associated periodic syndrome (TRAPS), who showed first symptoms at the age of four months.
  • Thus, he obtained a long-term therapy with cortisone, chlorambucile, methotrexate and cyclophosphamide.
  • At the age of 14 he developed a secondary acute myeloblastic leukemia.
  • However, such chromosomes are observed frequently after chemo- or radiotherapy and in secondary, i.e. therapy related AML (tAML).
  • Thus, AML in this case may result from a long-term therapy of TRAPS with methotrexate, cyclophosphamide, chlorambucile and cortisone.
  • [MeSH-major] Arthritis, Juvenile / drug therapy. Chromosome Aberrations. Leukemia, Myeloid, Acute / genetics. Receptors, Tumor Necrosis Factor / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Juvenile Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14534697.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Tumor Necrosis Factor
  •  go-up   go-down


54. Duda J, Zoger S: Presentation of M4 acute myeloid leukemia in anuric renal failure with hyperuricemia and enlarged kidneys. J Pediatr Hematol Oncol; 2002 Jan;24(1):55-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presentation of M4 acute myeloid leukemia in anuric renal failure with hyperuricemia and enlarged kidneys.
  • Extramedullary acute myeloid leukemia (AML) is not uncommon.
  • By contrast, acute tumor lysis syndrome is rare in AML, especially at initial diagnosis.
  • The authors report the management of a patient with AML who had acute tumor lysis syndrome that was probably potentiated by renal leukemia and resulted in renal failure.
  • This patient achieved remission with dose-modified induction chemotherapy administered while he was dialysis-dependent.
  • [MeSH-major] Acute Kidney Injury / etiology. Anuria / etiology. Kidney / pathology. Leukemia, Myelomonocytic, Acute / diagnosis
  • [MeSH-minor] African Continental Ancestry Group. Antineoplastic Combined Chemotherapy Protocols. Bone Marrow Transplantation. California. Child. Combined Modality Therapy. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11902742.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Ozturk A, Orhan B, Turken O, Etiz D, Yaylaci M, Uskent N: Acute myeloblastic leukemia achieving complete remission with amifostine alone. Leuk Lymphoma; 2002 Feb;43(2):451-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloblastic leukemia achieving complete remission with amifostine alone.
  • Apart from the cytoprotective role, Amifostine could also be used in the treatment of hematologic malignancies such as myelodysplastic syndrome (MDS) and acute myeloblastic leukemia (AML), as a treatment option or for potentiating the effects of cytotoxic agents.
  • We tried to use Amifostine in a patient with AML, which did not respond to conventional cytotoxic chemotherapy and aimed to publish the results.
  • The patient was a 77-year-old male patient, he was diagnosed as AML by peripheral blood smear and bone marrow aspiration.
  • Treatment commenced with low dose cytosine arabinoside (Ara-C) but the therapy should have ceased due to patient intolerance.
  • The patient refused further therapy and he was offered to have Amifostine treatment.
  • Amifostine was administered 200 mg/m2 three times a week, with ciprofloxacin, pentoxifyllin and dexamethasone.
  • Amifostine treatment was restarted after he relapsed but this time he did not respond to the treatment and died of gastrointestinal bleeding on the 8th week of treatment.
  • [MeSH-major] Amifostine / administration & dosage. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Fatal Outcome. Humans. Male. Recurrence. Remission Induction / methods

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11999588.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] M487QF2F4V / Amifostine
  •  go-up   go-down


56. Slavcheva V, Lukanov T, Tzvetkov N: Two cases of extramedullary myeloid tumor in patients with continuous remission of acute myeloblastic leukemia. J BUON; 2008 Oct-Dec;13(4):589-92
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of extramedullary myeloid tumor in patients with continuous remission of acute myeloblastic leukemia.
  • Myeloid sarcoma is described as tumor mass consisting of myeloblasts or immature myeloid cells, involving extramedullary tissues.
  • It can be initial manifestation of myeloproliferative disorders or relapse of previously treated acute myeloblastic leukemia (AML).
  • We present two patients, one with AML-M2 and the other with acute promyelocytic leukemia (APL)-M3.
  • After remission induced by conventional chemotherapy, which continued for 3 and 10 years respectively, a myeloid sarcoma was diagnosed.
  • Despite this, the patients received chemotherapy.
  • The APL-M3 patient was treated with radiotherapy to the involved supraclavicular lymph node which was followed by chemotherapy.
  • Two years after the diagnosis of myeloid sarcoma the patient died of haemorrhagic stroke.
  • The patient with AML-M2 continued treatment with polychemotherapy.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemia, Promyelocytic, Acute / pathology. Sarcoma, Myeloid / pathology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145688.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


57. Siddiqui AA, Rehman NU: Extradural Granulocytic sarcoma causing acute paraparesis. J Coll Physicians Surg Pak; 2004 Jan;14(1):45-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extradural Granulocytic sarcoma causing acute paraparesis.
  • A case of 9 years old female presenting with rapidly progressive paraparesis during remission phase of acute myeloblastic leukemia is reported.
  • The patient showed a dramatic neurological recovery after spinal cord decompression and subsequently treated with appropriate chemotherapy and local radiotherapy.
  • [MeSH-major] Paraparesis / etiology. Sarcoma, Myeloid / diagnosis. Spinal Cord Compression / etiology. Spinal Neoplasms / diagnosis
  • [MeSH-minor] Child. Female. Humans. Leukemia, Myeloid, Acute / complications. Magnetic Resonance Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14764263.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


58. Niiya H, Hasegawa H, Iwamasa K, Yasukawa M, Fujita S: [Two cases of cardiac aspergillosis with initial onset of arrhythmia during therapy of acute leukemia]. Kansenshogaku Zasshi; 2001 Feb;75(2):155-60
MedlinePlus Health Information. consumer health - Heart Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of cardiac aspergillosis with initial onset of arrhythmia during therapy of acute leukemia].
  • We have reported two women, aged 86 and 84 years, with cardiac aspergillosis with initial onset of arrhythmia during chemotherapy of acute myeloblastic leukemia and primary plasma cell leukemia, respectively.
  • In leukopenia followed by chemotherapy, they suddenly had arrhythmias with high fever.
  • [MeSH-major] Arrhythmias, Cardiac / etiology. Aspergillosis / complications. Heart Diseases / complications. Leukemia, Myeloid, Acute / complications


59. Carré M, Cahn JY: [Should we treat patients over 65 years with acute myeloblastic leukemia?]. Rev Prat; 2010 Dec 20;60(10):1423-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Should we treat patients over 65 years with acute myeloblastic leukemia?].
  • [Transliterated title] Traiter ou non un patient de plus de 65 ans ayant une leucémie aiguë myéloblastique?
  • The incidence of acute myeloblastic leukemia increases with age.
  • The unfavorable biology of the disease, comorbidities, and significant side effects of the intensive treatment make treatment decisions difficult.
  • Some of them will be treated successfully using intensive chemotherapy, while a majority of them will fail.
  • Older patients are heterogeneous and enrolling them in investigational therapy is justified, according to proven methods to stratify them.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Decision Making. Leukemia, Myeloid, Acute / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21425545.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


60. Veyret C, Levy C, Chollet P, Merrouche Y, Roche H, Kerbrat P, Fumoleau P, Fargeot P, Clavere P, Chevallier B: Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial. Cancer; 2006 Dec 1;107(11):2535-44
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
  • BACKGROUND: The authors evaluated the long-term efficacy and side effects in patients with nonmetastatic, unilateral, inflammatory breast cancer (IBC) who received homogeneous treatment with intensive induction chemotherapy followed by a maintenance regimen.
  • Locoregional treatment consisted of surgery and/or radiotherapy.
  • Maintenance chemotherapy was FEC 75 (fluorouracil 500 mg/m(2), epirubicin 75 mg/m(2), and cyclophosphamide 500 mg/m(2) on Day 1 every 21 days for 4 cycles).
  • No hormone treatment was allowed.
  • After a median 10 years of follow-up, the disease-free survival (DFS) and overall survival (OS) rates were 35.7% and 41.2%, respectively.
  • Five patients developed a temporary decrease in left ventricular ejection fraction without congestive heart failure.
  • In the lenograstim group, 1 patient developed acute myeloblastic leukemia M2, and 1 patient developed myelodysplastic syndrome.
  • CONCLUSIONS: FEC-HD induction chemotherapy followed by FEC 75 maintenance regimen had moderate and acute long-term toxicities and lead to high DFS and OS rates in patients with IBC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Dose-Response Relationship, Drug. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / adverse effects. Humans. Inflammation. Placebos. Recombinant Proteins / administration & dosage. Recombinant Proteins / adverse effects. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - TEN.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 17054108.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Placebos; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3Z8479ZZ5X / Epirubicin; 6WS4C399GB / lenograstim; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; FEC protocol
  •  go-up   go-down


61. Elouennass M, Doghmi K, Fagot T, Soler C, Mac Nab C, Foissaud V, De Revel T, Hervé V: [Hepatosplenic and kidneys candidasis complicating an acute myeloblastic leukemia. A case treated with voriconazole and caspofungin]. Ann Biol Clin (Paris); 2005 Jul-Aug;63(4):423-7
Hazardous Substances Data Bank. CASPOFUNGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatosplenic and kidneys candidasis complicating an acute myeloblastic leukemia. A case treated with voriconazole and caspofungin].
  • [Transliterated title] Candidose hépato-spléno-rénale compliquant une leucémie aiguë myéloblastique. A propos d'un cas traité par l'association voriconazole et caspofungine.
  • We report the observation of hepato-splenic and kidneys candidiasis complicating the chemotherapy of a myeloblastic leukemia (LAM5b).
  • [MeSH-major] Antifungal Agents / therapeutic use. Candidiasis / drug therapy. Kidney Diseases / microbiology. Leukemia, Myeloid, Acute / microbiology. Liver Diseases / microbiology. Peptides, Cyclic / therapeutic use. Pyrimidines / therapeutic use. Splenic Diseases / microbiology. Triazoles / therapeutic use
  • [MeSH-minor] Adult. Echinocandins. Female. Humans. Tomography, X-Ray Computed. Voriconazole


62. Monzo M, Brunet S, Urbano-Ispizua A, Navarro A, Perea G, Esteve J, Artells R, Granell M, Berlanga J, Ribera JM, Bueno J, Llorente A, Guardia R, Tormo M, Torres P, Nomdedéu JF, Montserrat E, Sierra J, CETLAM: Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood; 2006 Jun 15;107(12):4871-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia.
  • Current prognostic factors for acute myeloblastic leukemia (AML) are not sufficient to accurately predict the group of patients in the intermediate-risk category who will successfully respond to treatment.
  • We used the allelic discrimination method to identify polymorphisms in GSTT1, SULT1C2, CDA, SXR (drug metabolic pathways), XPD, XPA, XPG, ERCC1, TOP2A (DNA repair), VEGF (angiogenesis), and MDR1 (multidrug resistance) genes in 110 adult patients with intermediate-risk AML, enrolled in the CETLAM-99 prospective trial.
  • A multivariate prognostic model adjusted for age, white blood cell (WBC) count, French-American-British group, cytogenetics, MLL rearrangement, internal tandem duplication of FLT3 (FLT3-ITD), induction courses to achieve complete remission, and germline polymorphisms, was used to detect independent risk factors associated with clinical outcome.
  • This analysis showed an increased risk of refractoriness to chemotherapy in the group of patients with XPA variant alleles (RR = 14; P = .02).
  • These findings might be useful in selecting risk-adapted treatment strategies in intermediate-risk AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / mortality. Neoplasm Proteins / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adult. Alleles. Disease-Free Survival. Female. Heterozygote. Humans. Leukocyte Count. Male. Multivariate Analysis. Prognosis. Prospective Studies. Recurrence. Remission Induction. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507781.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


63. Yamamoto K, Nagata K, Morita Y, Hamaguchi H: [Successful treatment with G-CSF and continuous infusion of low-dose cytarabine and etoposide for therapy-related acute myeloid leukemia developed during chemotherapy for malignant lymphoma]. Rinsho Ketsueki; 2002 Jun;43(6):488-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment with G-CSF and continuous infusion of low-dose cytarabine and etoposide for therapy-related acute myeloid leukemia developed during chemotherapy for malignant lymphoma].
  • He had received 8 cycles of chemotherapy including doxorubicin in China.
  • He was diagnosed as having therapy-related acute myeloblastic leukemia (AML).
  • Because of hypoplastic bone marrow, induction therapy with the CAG regimen including cytarabine, aclarubicin and granulocyte-colony stimulating factor (G-CSF) was started, but no apparent effect was observed.
  • Although it has been shown that the CAG regimen is effective for refractory and/or secondary AML, our results indicate that the AVG regimen should be tried for cases of AML resistant to the CAG regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myelomonocytic, Acute / etiology. Lymphoma, Non-Hodgkin / drug therapy. Neoplasms, Second Primary / etiology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12134707.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


64. Lemez P, Gáliková J, Michalová K, Dvoráková D, MacWhannell A, Zemanová Z, Stejskal J: [Patients older than 80 years with de novo acute myeloid leukemias without erythroblastic and/or megakaryocytic dysplasia achieve complete remission and longer survival after classical chemotherapy 3 + 7]. Vnitr Lek; 2010 Jan;56(1):37-43
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Patients older than 80 years with de novo acute myeloid leukemias without erythroblastic and/or megakaryocytic dysplasia achieve complete remission and longer survival after classical chemotherapy 3 + 7].
  • [Transliterated title] Nemocní starsí 80 let s de novo akutními myeloidními leukemiemi bez dysplazie v erytroblastické 8/nebo megakaryocytární radĕ dosahují kompletní remise a delsího prezlití po klasické chemoterapii 3+7.
  • Chemotherapy in most patients with AML over 80 years of age is not recommended because their median survival is about 1 month.
  • The aim of our study was to identify patients in this age group who might achieve complete remission with standard dose chemotherapy.
  • We report 9 consecutive patients with de novo AML diagnosed and treated in 1992-2008.
  • All bone marrow samples were hypercellular, classified as FAB types M2 in 2 cases, M4 in 6, and M5 in one case.
  • Three patients opted for supportive or palliative therapy and survived 1-4 months.
  • Six patients received standard dose chemotherapy.
  • Two patients with a normal karyotype had resistant AML and survived 1.0 and 2.7 months; one patient with a complex karyotype died of septic shock on the 10th day of therapy.
  • Three remaining patients with AML M4, a normal karyotype but without EMD, achieved complete remission in spite of co-morbidities and a poor performance status.
  • Two of them survived 18.6 and 28 months on maintenance therapy, the third 16.5 months without it.
  • Very elderly AML patients without EMD appear to represent a favorable prognostic biological category (single-lineage AML) that show a good response to standard dose chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20184110.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


65. Taguchi A, Tominaga T, Nakamori Y, Miyazaki M, Shinohara K: Two cases of acute myeloblastic leukemia evolving from aplastic anemia. Int J Hematol; 2003 Jun;77(5):471-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of acute myeloblastic leukemia evolving from aplastic anemia.
  • Two cases of acute myeloblastic leukemia (AML) evolving from aplastic anemia are presented.
  • The first case was diagnosed 18 years ago, and treatment with bolus methylprednisolone, prednisolone, and androgens resulted in partial hematological response.
  • Severe pancytopenia recurred, and AML M0 by French-American-British classification developed.
  • The patient had HLA DRB1*1501, and treatment with granulocyte colony-stimulating factor (G-CSF), cyclosporine, and methenolone resulted in complete hematological response.
  • Thrombocytopenia recurred and did not respond to cyclosporine and methenolone or to later treatment with antithymocyte globulin, and AML M1 developed.
  • These patients were treated with cytosine arabinoside, aclacinomycin, and G-CSF (CAG) chemotherapy, and the number of leukemic cells decreased substantially.
  • However, pancytopenia after CAG chemotherapy persisted, and the first patient died of pneumonia and the second patient of cerebral hemorrhage.
  • [MeSH-major] Anemia, Aplastic / pathology. Leukemia, Myeloid, Acute / etiology
  • [MeSH-minor] Child. Cytogenetic Analysis. DNA Mutational Analysis. Fatal Outcome. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. HLA-DR Antigens / analysis. Hormones / therapeutic use. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Pancytopenia / etiology

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Aplastic Anemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Aplastic Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 May 1;99(9):3129-35 [11964274.001]
  • [Cites] Exp Hematol. 1987 Dec;15(11):1134-9 [3315724.001]
  • [Cites] Blood. 2002 Dec 1;100(12):3897-902 [12393738.001]
  • [Cites] Br J Haematol. 1988 Sep;70(1):55-62 [3179229.001]
  • [Cites] Blood. 1992 Mar 15;79(6):1385-92 [1547338.001]
  • [Cites] Blood. 1996 Sep 15;88(6):1930-5 [8822909.001]
  • [Cites] Am J Med. 1981 Oct;71(4):543-51 [7282742.001]
  • [Cites] Nature. 1987 Jun 4-10;327(6121):430-2 [3295562.001]
  • [Cites] Blood. 2000 Mar 15;95(6):1931-4 [10706857.001]
  • [Cites] Br Med J. 1971 Jun 26;2(5764):743-5 [5282950.001]
  • [Cites] Br J Haematol. 1999 Feb;104(2):271-4 [10050707.001]
  • [Cites] Blood. 1992 May 15;79(10):2566-71 [1586708.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1009-13 [9242530.001]
  • [Cites] Blood. 2002 Aug 1;100(3):1031-7 [12130519.001]
  • [Cites] Leukemia. 1995 Jan;9(1):10-4 [7531259.001]
  • [Cites] Ann Intern Med. 2002 Apr 2;136(7):534-46 [11926789.001]
  • [Cites] Blood. 2002 Aug 1;100(3):786-90 [12130487.001]
  • [Cites] Leukemia. 2002 Dec;16(12):2366-78 [12454741.001]
  • [Cites] Semin Hematol. 2000 Jan;37(1):91-101 [10676914.001]
  • [Cites] Blood. 1990 Dec 1;76(11):2222-8 [2257296.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3513-9 [11739151.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] Br J Haematol. 1988 Jul;69(3):413-8 [3044440.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):505-11 [10583249.001]
  • [Cites] Br J Haematol. 1991 Apr;77(4):447-52 [2025570.001]
  • [Cites] Br J Haematol. 1989 Sep;73(1):121-6 [2803967.001]
  • [Cites] J Clin Pathol. 1988 Jul;41(7):763-7 [3410972.001]
  • [Cites] Blood. 1994 Dec 15;84(12):4257-61 [7994040.001]
  • [Cites] Blood. 1995 Nov 1;86(9):3542-52 [7579462.001]
  • [Cites] N Engl J Med. 1993 Oct 14;329(16):1152-7 [8377778.001]
  • [Cites] Blood. 1987 Oct;70(4):1046-52 [3651599.001]
  • [Cites] N Engl J Med. 1992 May 7;326(19):1294-5 [1373226.001]
  • (PMID = 12841385.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / HLA-DR Antigens; 0 / Hormones; 0 / Immunosuppressive Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


66. Vanderhofstadt M, André M, Lonchay C, Levecque P, Holemans X, Canon JL, D'Hondt L: Clostridium tertium bacteremia: contamination or true pathogen? A report of two cases and a review of the literature. Int J Infect Dis; 2010 Sep;14 Suppl 3:e335-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient was being treated for first-relapse acute myeloblastic leukemia, while the second was receiving high-dose chemotherapy with hematopoietic stem cell support for non-Hodgkin lymphoma.
  • At the time that C. tertium was identified, the first patient was completely asymptomatic, while the second was highly febrile.
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Female. Humans. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / therapy. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / therapy. Male. Middle Aged. Neutropenia / complications. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20598605.001).
  • [ISSN] 1878-3511
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


67. Shin HJ, Chung JS, Choi YJ, Cho GJ: A pilot study of priming with granulocyte macrophage colony-stimulating factor plus all-trans retinoic acid combined with remission induction chemotherapy in patients with acute myeloid leukemia. Am J Clin Oncol; 2009 Jun;32(3):227-32
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of priming with granulocyte macrophage colony-stimulating factor plus all-trans retinoic acid combined with remission induction chemotherapy in patients with acute myeloid leukemia.
  • OBJECTIVES: Priming with granulocyte macrophage colony-stimulating factor (GM-CSF) plus all-trans retinoic acid (ATRA) during induction chemotherapy may enhance response rates and survival in patients with acute myeloid leukemia (AML) due to the differentiation of human myeloblastic leukemia cells into granulocytes.
  • METHODS: GM-CSF was administered to patients during induction chemotherapy and ATRA was ingested orally on days 1 to 14.
  • Patients undergoing a regimen with GM-CSF and ATRA were evaluated as compared with a historical control group of subjects.
  • Two-year probabilities were 45.5% (study group) and 47.4% (control group) for disease-free survival and 38.5% (study group) and 36.2% (control group) for overall survival.
  • CONCLUSIONS: Priming with GM-CSF plus ATRA during anthracycline-based chemotherapy is feasible in terms of response rate, but the toxicity of the regimen is significant.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adult. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Pilot Projects. Prognosis. Remission Induction. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433969.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


68. Xavier L, Cunha M, Gonçalves C, Teixeira Mdos A, Coutinho J, Ribeiro AC, Lima M: Hematological remission and long term hematological control of acute myeloblastic leukemia induced and maintained by granulocyte-colony stimulating factor (G-CSF) therapy. Leuk Lymphoma; 2003 Dec;44(12):2137-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematological remission and long term hematological control of acute myeloblastic leukemia induced and maintained by granulocyte-colony stimulating factor (G-CSF) therapy.
  • We describe a case of a patient with CD34+, TdT+, CD13-, CD33-, MPO- undifferentiated acute leukemia who refused chemotherapy and who achieved complete hematological remission 14 months after the diagnosis, during a short course of granulocyte-colony stimulating factor (G-CSF) for neutropenia and life threatening infection.
  • Five months after withdrawing the G-CSF therapy a second relapse was observed; G-CSF was tried again with success, resulting in a very good hematological response that was sustained by G-CSF maintenance therapy.
  • One year latter there was the need of increasing the doses of G-CSF in order to obtain the same hematological effect, at same time blast cells acquired a more mature CD34+, TdT-, CD13+, CD33-, MPO+ myeloid phenotype.
  • Finally, the patient developed progressive neutropenia, anemia, thrombocytopenia and acute leukemia in spite of G-CSF therapy, dying 64 months after initial diagnosis (50 months after starting G-CSF therapy) with overt G-CSF resistant acute myeloblastic leukemia (AML), after failure of conventional induction chemotherapy.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Antigens, CD / biosynthesis. Antigens, CD13 / biosynthesis. Antigens, CD34 / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. DNA Nucleotidylexotransferase / biosynthesis. Female. Humans. Middle Aged. Peroxidase / metabolism. Phenotype. Remission Induction. Sialic Acid Binding Ig-like Lectin 3. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14959860.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 143011-72-7 / Granulocyte Colony-Stimulating Factor; EC 1.11.1.7 / Peroxidase; EC 2.7.7.31 / DNA Nucleotidylexotransferase; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


69. Handa T, Yamamoto K, Tadokoro J, Kikkawa Y, Tsurumi S, Nakamura Y, Saito K, Uzuka Y, Saito Y, Furusawa S: [CD19-positive acute myeloblastic leukemia developed 12 years after the onset of hypereosinophilic syndrome]. Rinsho Ketsueki; 2000 Sep;41(9):723-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CD19-positive acute myeloblastic leukemia developed 12 years after the onset of hypereosinophilic syndrome].
  • We report a rare case of hypereosinophilic syndrome (HES) that developed to acute myeloblastic leukemia (AML).
  • The patient, a 34-year-old man, presented with eosinophilia of unknown origin (white blood cells 38,200/microliter with 74% eosinophils) and pericardial effusion, and was diagnosed as having HES with a normal karyotype.
  • He received four cycles of combination chemotherapy including cyclophosphamide, cytosine arabinoside and vindesine, and thereafter remained in remission.
  • CD19-positive AML was diagnosed.
  • The patient received combination chemotherapy and achieved a complete remission.
  • Chromosome aberrations involving 7q as well as 21q22 suggested that the initial chemotherapy for HES might have been implicated in the pathogenesis of acute leukemia in this case.
  • [MeSH-major] Antigens, CD19 / blood. Hypereosinophilic Syndrome / complications. Leukemia, Myeloid, Acute / etiology
  • [MeSH-minor] Humans. Male. Middle Aged. Time Factors

  • Genetic Alliance. consumer health - Hypereosinophilic syndromes.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11070933.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antigens, CD19
  • [Number-of-references] 10
  •  go-up   go-down


70. Romano MF, Lamberti A, Bisogni R, Tassone P, Pagnini D, Storti G, Del Vecchio L, Turco MC, Venuta S: Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-kappa B/Rel- specific decoy oligodeoxynucleotides. Gene Ther; 2000 Jul;7(14):1234-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-kappa B/Rel- specific decoy oligodeoxynucleotides.
  • The activity of NF-kappa B/Rel nuclear factors is known to inhibit apoptosis in various cell types.
  • We investigated whether the subtraction of NF-kappa B/Rel activity influenced the response of 11 AML (M1, M2 and M4) patients' cells to AraC.
  • On the other hand, in 10 of the 11 samples tested, the decoy kappa B, but not the scrambled ODN significantly (P < 0.01 in a Student's t test) enhanced cell apoptotic response to AraC.
  • These findings indicate that NF-kappa B/Rel activity influences response to AraC in human primary myeloblastic cells, and suggests that the inhibition of NF-kappa B/Rel factors can improve the effect of chemotherapy in AML.
  • Gene Therapy (2000) 7, 1234-1237.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cytarabine / therapeutic use. Leukemia, Myeloid, Acute / pathology. Oligodeoxyribonucleotides / genetics
  • [MeSH-minor] Apoptosis / drug effects. Genes, rel / physiology. Humans. NF-kappa B / physiology. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10918492.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / NF-kappa B; 0 / Oligodeoxyribonucleotides; 04079A1RDZ / Cytarabine
  •  go-up   go-down


71. Hiçsönmez G, Cetin M, Aslan D, Ozyürek E: The role of short course of high-dose methylprednisolone in children with acute myeloblastic leukemia (FAB M2) presented with myeloid tumor. Pediatr Hematol Oncol; 2003 Jul-Aug;20(5):373-9
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of short course of high-dose methylprednisolone in children with acute myeloblastic leukemia (FAB M2) presented with myeloid tumor.
  • The authors have previously demonstrated a favorable effect of high-dose methylprednisolone (HDMP), which can induce differentiation and apoptosis of leukemic cells in children with acute myeloblastic leukemia (AML).
  • Here, they evaluate the effect of short-course HDMP in 2 children with acute myeloblastic leukemia (AML-M2) presented with myeloid tumor (MT).
  • Rapid cytoreduction in MT, peripheral blood, and bone marrow blasts was observed in both children following short-course (4 or 7 days) HDMP treatment, possibly due to HDMP-induced differentiation and apoptosis of leukemic cells.
  • The effects of HDMP should be explored in patients with other subtypes of AML who present with MT.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Methylprednisolone / administration & dosage
  • [MeSH-minor] Antigens, CD / drug effects. Bone Marrow Examination. Cell Differentiation / drug effects. Child. Child, Preschool. Drug Administration Schedule. Female. Humans. Male. Sarcoma, Myeloid / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12775535.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antineoplastic Agents; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


72. Fouillard L, Labopin M, Gratwohl A, Gluckman E, Frassoni F, Beelen DW, Willemze R, Montserrat E, Blaise D, Atienza AI, Sierra J, Santos M, Gorin NC, Rocha V, Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation: Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission. Haematologica; 2008 Jun;93(6):834-41
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
  • BACKGROUND: The possibility of performing syngeneic hematopoietic stem cell transplantation is rare and there are concerns about the absence of a graft-versus-leukemia effect following such a strategy.
  • We report the outcomes of a large series of adult patients who underwent syngeneic hematopoietic stem cell transplantation for acute myeloblastic leukemia or acute lymphoblastic leukemia.
  • DESIGN AND METHODS: The outcomes of all syngeneic transplants for acute myeloblastic or lymphoblastic leukemia reported to the European Group for Blood and Marrow Transplantation registry were analyzed; a study of prognostic factors was performed for those transplanted in first complete remission.
  • RESULTS: One hundred and sixty-two patients, 109 with acute myeloblastic leukemia and 53 with acute lymphoblastic leukemia, were identified; 116 were in first complete remission.
  • Most of the patients did not receive prophylaxis against graft-versus-host disease.
  • Nineteen patients developed acute graft-versus-host disease and only three patients developed chronic graft-versus-host disease.
  • At 5 years the non-relapse mortality was 8 +/- 5%, the relapse incidence 49 +/- 8% and the leukemia-free survival 43 +/- 3%.
  • Analysis of patients in first complete remission showed that the number of courses of chemotherapy required to induce first complete remission was the main risk factor: the leukemia-free survival at 5 years was 66 +/- 6% when first complete remission was reached after one induction course of chemotherapy and was only 20 +/- 9% when first complete remission was reached after at least two induction courses of chemotherapy (p = 0.0001); the relapse incidence was 30 +/- 6% and 54 +/- 10%, respectively (p = 0.007).
  • CONCLUSIONS: Outcomes were better for patients transplanted in first complete remission than in second complete remission or a more advanced phase of the disease.
  • When a syngeneic donor is available for patients with high risk acute leukemia, allotransplantation should be performed as soon as the first complete remission has been achieved, ideally with one course of chemotherapy.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Diseases in Twins. Female. Graft vs Host Disease. Humans. Male. Middle Aged. Recurrence. Remission Induction. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2008 Jun;93(6):801-5 [18515876.001]
  • (PMID = 18469352.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


73. Kröger N, Zander AR, Martinelli G, Ferrante P, Moraleda JM, Da Prada GA, Demirer T, Socie G, Rosti G, European Group for Blood and Marrow Transplantation: Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation. Ann Oncol; 2003 Apr;14(4):554-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation.
  • BACKGROUND: To determine the incidence of secondary myelodysplasia (sMDS) or acute myeloid leukemia (AML) in node-positive breast cancer patients who received high-dose chemotherapy (HDCT) followed by autologous stem-cell support as adjuvant therapy.
  • PATIENTS AND METHODS: The incidence of sMDS/AML was retrospectively assessed in 364 node-positive breast cancer patients who received HDCT followed by autologous stem-cell support as adjuvant therapy between November 1989 and December 1997 and were reported to the European Group for Blood and Marrow Transplantation registry.
  • After a median follow-up of 48 months (range 1-108 months) only one case of AML was observed, resulting in a crude incidence of 0.27%.
  • This case of AML was observed 18 months after HDCT consisting of three cycles of epirubicin and cyclophosphamide with a cumulative dose of epirubicin 960 mg and cyclophosphamide 19 g.
  • The French-American-British type of AML was M4, and the cytogenetic analysis showed a translocation t(9;11)(p22;q23).
  • CONCLUSIONS: In contrast to patients with malignant lymphoma there seems to be no increased risk of sMDS/AML after HDCT in breast cancer.


74. Caceres-Cortes JR: A potent anti-carcinoma and anti-acute myeloblastic leukemia agent, AG490. Anticancer Agents Med Chem; 2008 Oct;8(7):717-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A potent anti-carcinoma and anti-acute myeloblastic leukemia agent, AG490.
  • JAK-2, have emerged as essentials in cell survival for cervical carcinoma and acute myeloblastic leukemia, respectively.
  • These receptors and soluble cytoplasm networks have been studied in detail and finally pharmacological agents, targeted at key molecules, could be produced.
  • The highly conserved JAK-2/STAT-3, c-Kit, and HER-2 signaling pathways play pleiotropic roles during embryonic development and are important for the regulation of self-renewing tissues.
  • Inhibiting their action by AG490 represents a therapeutic approach for the treatment of individual types of cancer and several broad-spectrum.
  • [MeSH-major] Antineoplastic Agents. Leukemia, Myeloid, Acute / drug therapy. Tyrphostins
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Humans. Janus Kinase 2 / antagonists & inhibitors. Molecular Structure. Phosphorylation. Proto-Oncogene Proteins c-kit / metabolism. STAT3 Transcription Factor / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18855573.001).
  • [ISSN] 1871-5206
  • [Journal-full-title] Anti-cancer agents in medicinal chemistry
  • [ISO-abbreviation] Anticancer Agents Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / STAT3 Transcription Factor; 0 / Tyrphostins; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 95
  •  go-up   go-down


75. Inaoui R, Petit B, Jaccard A, Bertin P, Trèves R: Aggressive systemic mastocytosis. Joint Bone Spine; 2003 Feb;70(1):64-6
Hazardous Substances Data Bank. Alendronic acid .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case in a 72-year-old patient in whom the diagnosis of malignant mastocytosis required two bone marrow smears and three bone marrow biopsies examined using specific staining techniques.
  • Despite interferon therapy, a mast-cell sarcoma of the sternum developed 1 year after symptom onset, followed 1 year later by acute myeloblastic leukemia, which was rapidly fatal.
  • [MeSH-minor] Aged. Alendronate / therapeutic use. Bone Marrow Cells / enzymology. Bone Marrow Cells / pathology. Fatal Outcome. Female. Humans. Interferon-alpha / therapeutic use. Leukemia, Myeloid, Acute / pathology. Mast Cells / enzymology. Mast Cells / pathology. Mast-Cell Sarcoma / pathology. Neoplasms, Multiple Primary. Osteoporosis, Postmenopausal / drug therapy. Prednisone / therapeutic use. Serine Endopeptidases / metabolism. Tryptases

  • Genetic Alliance. consumer health - Aggressive Systemic Mastocytosis.
  • Genetic Alliance. consumer health - Mast cell disease.
  • Genetic Alliance. consumer health - Systemic mastocytosis.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12639621.001).
  • [ISSN] 1297-319X
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Interferon-alpha; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.59 / Tryptases; VB0R961HZT / Prednisone; X1J18R4W8P / Alendronate
  •  go-up   go-down


76. Horikoshi A, Takei K, Iriyama N, Uenogawa K, Ishizuka H, Shiraiwa H, Hosokawa Y, Sawada S, Kitoh T: Effect of L-asparaginase combined with vincristine and prednisolone on acute myeloblastic leukemia (M0) associated with non-Hodgkin lymphoma. Acta Haematol; 2009;122(1):54-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of L-asparaginase combined with vincristine and prednisolone on acute myeloblastic leukemia (M0) associated with non-Hodgkin lymphoma.
  • She was eventually diagnosed as having acute myeloblastic leukemia (AML;.
  • We investigated the therapeutic efficacy of L-asparaginase (L-Asp), vincristine and prednisolone for both her AML and NHL.
  • Asparagine synthetase (AS) activity in her AML blast cells was undetectable.
  • A lymph node biopsy specimen revealed NHL of the marginal zone B cell type.
  • Complete remission (CR) of AML and NHL was achieved.
  • CR of the AML lasted for 18 months without further consolidation therapy.
  • We conclude that L-Asp can be an effective drug for the treatment of AML in which blasts are negative for AS.
  • [MeSH-major] Asparaginase / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Prednisolone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aspartate-Ammonia Ligase / metabolism. Fatal Outcome. Female. Humans. Remission Induction

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel
  • (PMID = 19816010.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase; EC 6.3.1.1 / Aspartate-Ammonia Ligase
  •  go-up   go-down


77. Yang MH, Zhao MY, He YL, Wang MH, Wang Z, Xie M, Wu XS, Cao LZ: [Interaction of WAVE1 and genes involved in multiple drug resistance in children with acute myeloblastic leukemia]. Zhonghua Er Ke Za Zhi; 2010 Mar;48(3):175-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interaction of WAVE1 and genes involved in multiple drug resistance in children with acute myeloblastic leukemia].
  • OBJECTIVE: Multidrug resistance (MDR) is one of the primary causes of suboptimal outcomes in chemotherapy of children with acute myeloblastic leukemia (AML).
  • The mechanisms of drug transport resistance may chiefly contribute to MDR.
  • Expression and/or activity of P-glycoprotein (P-gp), multiple resistance-associated protein-1 (MRP1), lung-resistance related protein (LRP) and breast cancer resistance protein (BCRP) have been considered to be associated with unfavourable outcomes in pediatric AML patients.
  • In previous studies, we found WASP-family verprolin-homologous protein-1 (WAVE1) was involved in the MDR mechanisms in K562/A02 leukemia cells.
  • To investigate the expression of WAVE1, P-gp, MRP1, LRP/MVP and BCRP; and if WAVE1 is involved in MDR of human leukemia cell.
  • METHODS: WAVE1, P-gp, MRP1, LRP, BCRP mRNA and protein expression in bone marrow mononuclear cells (BMMCs) were measured by real-time fluorescence quantitative PCR (RQ-PCR) and Western blot in a cohort of 52 children with acute myeloblastic leukemia.
  • Furthermore, HL60 cells and HL60/ADR cells were transiently transfected with PCDNA3.1-WAVE1 reconstructed plasmid and specifically siRNA to WAVE1 respectively, and the expression of WAVE1, MRP1 and BCRP before and after transfection was assessed by real-time PCR and Western blot analysis. RESULTS:.
  • (1) The expression levels of WAVE1, P-gp, MRP, LRP and BCRP in refractory/relapsing group were much higher than that in complete continuous remission (CCR) group. (2) WAVE1 mRNA and protein expression in BMMCs of children were at higher levels when they were newly diagnosed or relapsed, compared with complete continuous remission. (3) The WAVE1 expression at mRNA and protein level in HL60/ADR cells was increased by about 353% and 95% respectively as compared with that in HL60 cells. (4) Overexpression of WAVE1 in HL60 cell lines upregulated the expression levels of MRP and BCRP (MRP mRNA and protein level were increased by about 16.54 times and 129% respectively, BCRP was increased by 4.93 times and 96%); whereas suppression of WAVE1 expression by RNA interference downregulated the expression levels of MRP1 and BCRP (MRP mRNA and protein level was only 11% and 43% of pre-disturbance respectively, BCRP was 14% and 71%).
  • CONCLUSIONS: Higher levels of WAVE1 in the BM indicate an unfavorable prognosis in children with AML.
  • WAVE1 is related to the development of AML and involved in the MDR mechanisms, and regulates the level of MRP1 and BCRP.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Leukemia, Myeloid, Acute / genetics. Wiskott-Aldrich Syndrome Protein Family / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Drug Resistance, Multiple / genetics. Female. Humans. Infant. Male. RNA, Small Interfering

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20426950.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / Wiskott-Aldrich Syndrome Protein Family
  •  go-up   go-down


78. Silva ML, Land MG, Maradei S, Otero L, Veith M, Brito G, Klumb C, Fernandez T, Pombo-de-Oliveira MS: Translocation (11;11)(p13- p15;q23) in a child with therapy-related acute myeloid leukemia following chemotherapy with DNA-topoisomerase II inhibitors for Langerhans cell histiocytosis. Cancer Genet Cytogenet; 2002 May;135(1):101-2
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation (11;11)(p13- p15;q23) in a child with therapy-related acute myeloid leukemia following chemotherapy with DNA-topoisomerase II inhibitors for Langerhans cell histiocytosis.
  • We report a new case of therapy-related acute myeloid leukemia in a child with Langerhans cell histiocytosis.
  • This patient was previously treated with a protocol of multidrug chemotherapy, containing a relatively low dose of etoposide (total dose of 900/m(2)).
  • Twenty-six months after the end of the therapy, the patient returned to the hospital with fever and anemia.
  • The bone marrow examination showed massive infiltration with French-American-British acute myeloid leukemia classification M4 blast cells.
  • The patient did not respond to an intensive treatment with high dose ARA-C and idarubicin.
  • The cytogenetic abnormality of the blast cells was a t(11;11)(p13 -15;q23), that has not been described before in a secondary leukemia case.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Enzyme Inhibitors / adverse effects. Etoposide / adverse effects. Histiocytosis, Langerhans-Cell / drug therapy. Leukemia, Myelomonocytic, Acute / genetics. Neoplasms, Second Primary / genetics. Topoisomerase II Inhibitors. Translocation, Genetic
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Cytarabine / administration & dosage. Drug Therapy, Combination. Fatal Outcome. Humans. Idarubicin / administration & dosage. Karyotyping. Male. Nuclear Pore Complex Proteins / genetics. Prednisolone / administration & dosage. Prednisolone / therapeutic use. Vinblastine / administration & dosage. Vinblastine / therapeutic use

  • Genetic Alliance. consumer health - Histiocytosis.
  • Genetic Alliance. consumer health - Langerhans cell histiocytosis.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12072208.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Nuclear Pore Complex Proteins; 0 / Topoisomerase II Inhibitors; 0 / nuclear pore complex protein 98; 04079A1RDZ / Cytarabine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 9PHQ9Y1OLM / Prednisolone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


79. Kiratli H, Demiroğlu H, Emeç S: Ocular relapse in acute myeloid leukemia (M4) with normal bone marrow. Int Ophthalmol; 2009 Aug;29(4):243-5
MedlinePlus Health Information. consumer health - Eye Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular relapse in acute myeloid leukemia (M4) with normal bone marrow.
  • A patient with the rare occurrence of ocular relapse of acute myeloid leukemia (AML) M4 while the bone marrow was normal is reported in this paper.
  • A 47-year-old woman with AML was treated with chemotherapy and went successfully into remission.
  • Although exceedingly rare, ocular extramedullary relapse in AML M4 heralds bone marrow recurrence and, despite intensive chemotherapy, the prognosis is dismal.
  • [MeSH-major] Bone Marrow / pathology. Eye / pathology. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / pathology. Sarcoma, Myeloid / etiology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Fatal Outcome. Female. Humans. Leukapheresis. Leukemic Infiltration / etiology. Middle Aged. Recurrence. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Feb 1;85(3):608-15 [10091734.001]
  • [Cites] N Z Med J. 1996 Jun 28;109(1024):242 [8769042.001]
  • [Cites] Hematol Oncol. 1999 Jun;17(2):45-52 [10521868.001]
  • [Cites] Bone Marrow Transplant. 1996 May;17(5):801-8 [8733701.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1800-16 [7602369.001]
  • [Cites] Am J Ophthalmol. 1999 Mar;127(3):361-3 [10088758.001]
  • (PMID = 18338107.001).
  • [ISSN] 1573-2630
  • [Journal-full-title] International ophthalmology
  • [ISO-abbreviation] Int Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


80. Simon A, Besuden M, Vezmar S, Hasan C, Lampe D, Kreutzberg S, Glasmacher A, Bode U, Fleischhack G: Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants. Support Care Cancer; 2007 Feb;15(2):213-20
Hazardous Substances Data Bank. Itraconazole .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants.
  • As a direct response to this increased environmental risk, itraconazole (ITC) was administered for primary prophylaxis in pediatric cancer patients for whom a particular high risk of IA was anticipated due to prolonged severe neutropenia (>10 days), autologous stem cell transplantation, acute myeloblastic leukemia or relapsed acute lymphoblastic leukemia, or high-dose steroids >3 weeks.
  • Trough concentrations were measured in plasma with high-performance liquid chromatography after at least 7 days of treatment.
  • Drug monitoring and meticulous consideration of possible interactions and adverse effects are mandatory.
  • [MeSH-major] Antifungal Agents / administration & dosage. Aspergillosis / prevention & control. Itraconazole / administration & dosage. Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Aspergillus / drug effects. Chemoprevention. Child. Child, Preschool. Female. Humans. Immunocompromised Host. Infant. Leukemia / therapy. Lymphoma / therapy. Male. Neuroblastoma / therapy. Neutropenia / complications. Prospective Studies. Stem Cell Transplantation / adverse effects

  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dis Child. 2003 Mar;88(3):258-60 [12598396.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Jan;28(1):33-5 [16394890.001]
  • [Cites] N Engl J Med. 2002 Dec 26;347(26):2173-4 [12501236.001]
  • [Cites] Bone Marrow Transplant. 1999 Nov;24(10):1089-93 [10578159.001]
  • [Cites] Drugs. 2002;62(10):1481-502 [12093316.001]
  • [Cites] Clin Microbiol Infect. 2004 Mar;10 Suppl 1:86-95 [14748805.001]
  • [Cites] Am J Clin Dermatol. 2004;5(4):225-37 [15301570.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Apr;25(4):286-91 [12679641.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2004 Apr;23(4):256-70 [15015031.001]
  • [Cites] Clin Pharmacokinet. 2005;44(5):441-66 [15871633.001]
  • [Cites] J Antimicrob Chemother. 2005 Sep;56 Suppl 1:i33-i38 [16120632.001]
  • [Cites] Mycoses. 2002;45 Suppl 3:48-55 [12690972.001]
  • [Cites] Infect Control Hosp Epidemiol. 2000 Sep;21(9):592-6 [11001263.001]
  • [Cites] J Hosp Infect. 1998 Jun;39(2):95-109 [9651854.001]
  • [Cites] J Chromatogr A. 2004 Mar 26;1031(1-2):307-13 [15058598.001]
  • [Cites] Ther Drug Monit. 1999 Jun;21(3):304-9 [10365642.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4384-93 [15514380.001]
  • [Cites] Pediatr Crit Care Med. 2004 Nov;5(6):561-5 [15530193.001]
  • [Cites] Clin Infect Dis. 2001 Feb 1;32(3):358-66 [11170942.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Oct;24(7):591 [12368705.001]
  • [Cites] Am J Med. 1989 Jun;86(6 Pt 2):791-800 [2543220.001]
  • [Cites] Acta Paediatr. 2001 Oct;90(10):1204-7 [11697438.001]
  • [Cites] Clin Infect Dis. 2001 Oct 15;33(8):e83-90 [11550120.001]
  • [Cites] J Hosp Infect. 2004 Feb;56(2):93-100; quiz 163 [15019219.001]
  • [Cites] Clin Infect Dis. 2002 Jan 1;34(1):7-14 [11731939.001]
  • [Cites] J Clin Pharmacol. 1999 Nov;39(11):1109-25 [10579141.001]
  • [Cites] Pediatr Clin North Am. 2005 Jun;52(3):895-915, viii [15925667.001]
  • [Cites] J Antimicrob Chemother. 2005 Sep;56 Suppl 1:i23-i32 [16120631.001]
  • [Cites] Antimicrob Agents Chemother. 1998 Feb;42(2):404-8 [9527794.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1338-43 [9737680.001]
  • [Cites] Antimicrob Agents Chemother. 2001 May;45(5):1561-4 [11302829.001]
  • [Cites] Indian J Pediatr. 2004 Nov;71(11):973-7 [15572815.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1557-9 [14504090.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1527-33 [14525770.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Aug;46(8):2554-63 [12121932.001]
  • [Cites] Mycoses. 1999;42(11-12):591-600 [10680434.001]
  • [Cites] Infect Control Hosp Epidemiol. 2003 Jul;24(7):472-6 [12887233.001]
  • [Cites] J Clin Pharmacol. 1997 Jun;37(6):535-40 [9208361.001]
  • [Cites] J Antimicrob Chemother. 2005 Sep;56 Suppl 1:i17-i22 [16120630.001]
  • (PMID = 16944217.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Antineoplastic Agents; 304NUG5GF4 / Itraconazole
  •  go-up   go-down


81. Shimohakamada Y, Shinohara K, Fukuda N: Remission of acute myeloblastic leukemia after severe pneumonia treated with high-dose methylprednisolone. Int J Hematol; 2001 Aug;74(2):173-7
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of acute myeloblastic leukemia after severe pneumonia treated with high-dose methylprednisolone.
  • We report a case of acute myeloblastic leukemia (AML)-M2 (by French-American-British classification) with t(8;21) (q22:q22) that was complicated with severe pneumonia.
  • High-dose methylprednisolone was administered, and the leukemic cells disappeared without chemotherapy, although dysplastic hematopoietic cells were observed transiently after the first therapy.
  • After the disappearance of leukemic cells, FISH for AML1 splitting was negative, and real-time PCR results for quantitative chimeric AML1/ MTG8 mRNA were less than the detectable level, however, RT-PCR results for AML1/MTG8 mRNA remained positive.
  • [MeSH-major] Anti-Inflammatory Agents / administration & dosage. Leukemia, Myeloid, Acute / complications. Methylprednisolone / administration & dosage. Pneumonia / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11594518.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


82. Johansson B, Axelsson P, Billström R, Strömbeck B, Arheden K, Olofsson T, Cervin A, Adriansson M, Tanke HJ, Mitelman F, Fioretos T: Isodicentric 7p, idic(7)(q11.2), in acute myeloid leukemia associated with older age and favorable response to induction chemotherapy: a new clinical entity? Genes Chromosomes Cancer; 2001 Mar;30(3):261-6
Hazardous Substances Data Bank. THIOGUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isodicentric 7p, idic(7)(q11.2), in acute myeloid leukemia associated with older age and favorable response to induction chemotherapy: a new clinical entity?
  • Three adult de novo acute myeloid leukemias (AML M1, M2, and M4) with an isochromosome 7p are presented.
  • Although the patients were elderly--68, 72, and 78 years old--they all responded very well to chemotherapy, achieving complete remission lasting more than a year.
  • Thus, the abnormality should formally be designated idic(7)(q11.2).
  • Furthermore, the breakpoints also differed within one of the cases, being located on both the proximal and the distal side of the most centromeric probe used.
  • Based on our three patients, as well as on a previously reported 82-year-old patient with AML M2 and idic(7)(q11) as the only chromosomal change, we suggest that this abnormality, as the sole anomaly, is associated with AML in elderly patients who display a good response to induction chemotherapy and, hence, have a favorable prognosis.
  • [MeSH-major] Aging / genetics. Chromosomes, Human, Pair 7 / genetics. Isochromosomes / genetics. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Banding. Cytarabine / therapeutic use. Female. Humans. Idarubicin / therapeutic use. In Situ Hybridization, Fluorescence / methods. Leukemia, Myelomonocytic, Acute / drug therapy. Leukemia, Myelomonocytic, Acute / genetics. Male. Remission Induction. Thioguanine / therapeutic use

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 11170283.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; FTK8U1GZNX / Thioguanine; ZRP63D75JW / Idarubicin; LAI regimen
  •  go-up   go-down


83. Elmas SA, Cetin M, Tuncer M, Hiçsönmez G: Myeloprotective effect of short-course high-dose methylprednisolone treatment before consolidation therapy in children with acute myeloblastic leukemia. Am J Hematol; 2005 Sep;80(1):1-5
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloprotective effect of short-course high-dose methylprednisolone treatment before consolidation therapy in children with acute myeloblastic leukemia.
  • In our previous studies, short-course high-dose methylprednisolone (HDMP) has been shown to shorten the chemotherapy-induced neutropenic period by stimulating the CD34(+) hematopoietic progenitor cells in children with acute leukemia.
  • In this study, we investigate the role of short-course HDMP on induction of a myeloprotective effect when administered before consolidation therapy consisting of high-dose cytosine arabinoside and daunorubicin.
  • Thirty-four consecutive newly diagnosed children with acute myeloblastic leukemia (AML) who received 64 courses of consolidation regimen were entered into the study.
  • The patients received HDMP (group A) at a daily dose of 30 mg/kg methylprednisolone starting 4 days before the initiation of consolidation therapy.
  • The WBC count increased significantly from 3 x 10(9)/L to 6.4 x 10(9)/L, and ANC increased from 1.5 x 10(9)/L to 3.9 x 10(9)/L after 4 days of HDMP treatment in group A (P < 0.01).
  • Following high-dose chemotherapy, the median values of WBC and ANC also remained higher than the control values during the 16 days of the follow-up period.
  • The duration of hospitalization and the interval between two chemotherapy cycles were significantly decreased in group A when compared group B (9 +/- 2.7 vs. 14 +/- 2.7 days; 22 +/- 4.7 vs. 26 +/- 4.2 days, respectively) (P < 0.05).
  • Moreover, following consolidation therapy, the number of patients with ANC values below 0.5 x 10(9)/L was lower in group A when compared the group B.
  • In conclusion, the administration of short-course (4 days) HDMP before high-dose chemotherapy has been found to be beneficial for reducing the duration and severity of neutropenia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Glucocorticoids / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Methylprednisolone / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16138333.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


84. Yazar S, Eser B, Yalçin S, Sahin I, Koç AN: A case of pulmonary Microsporidiasis in an acute myeloblastic leukemia (AML) - M3 patient. Yonsei Med J; 2003 Feb;44(1):146-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of pulmonary Microsporidiasis in an acute myeloblastic leukemia (AML) - M3 patient.
  • Reported here is a case of microsporidiasis that occurred in an acute myeloblastic leukemia (AML)-M3 patient who underwent chemotherapy.
  • Fever, cough, expectorate and dyspnea were observed during the therapy.
  • Although he was given combined antibiotic therapy, there was no reduction in the fever.
  • The patient died due to sepsis and DIC just before receiving therapy for microsporidiasis.
  • Pulmonary infection with Microsporidia, although classically occurring in patients with HIV infection, may occur rarely in leukemia patients, especially if previously treated with systemic immune suppression.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Lung Diseases, Parasitic / complications. Microsporidiosis / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12619189.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


85. Santos-Machado TM, Zerbini MC, Cristofani LM, Azevedo PM, Almeida MT, Maluf PT Jr, Odone-Filho V: Simultaneous occurrence of advanced neuroblastoma and acute myeloid leukemia. Pediatr Hematol Oncol; 2001 Mar;18(2):129-35
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous occurrence of advanced neuroblastoma and acute myeloid leukemia.
  • The authors report the case of a 4-year-old boy with a diagnosis of stage IV neuroblastoma (NB), who had been treated with 6 cycles of cyclophosphamide, doxorubicin, cisplatin, and etoposide for 12 months.
  • The patient reached partial remission and presented a diagnosis of acute myelomonocytic leukemia (M4 AML), confirmed by immunophenotyping.
  • After 2 months of therapy for leukemia, the child died with both malignancies in activity.
  • The review leads to the conclusion that AML can occur as a secondary malignancy after the onset of the neuroblastoma, or be suggested by a misdiagnosis.
  • [MeSH-major] Leukemia, Myelomonocytic, Acute / etiology. Neoplasms, Second Primary / diagnosis. Neuroblastoma / drug therapy
  • [MeSH-minor] Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / toxicity. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / toxicity. Bone Marrow / pathology. Child, Preschool. Fatal Outcome. Humans. Immunohistochemistry. Immunophenotyping. Male. Neutropenia / etiology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11255731.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating
  •  go-up   go-down


86. Trus MR, Yang L, Suarez Saiz F, Bordeleau L, Jurisica I, Minden MD: The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia; 2005 Jul;19(7):1161-8
Hazardous Substances Data Bank. VALPROIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
  • Acute myeloblastic leukemia (AML) may be classified in a number of ways.
  • Using the French American British classification, the M3 form of the disease or acute promyelocytic leukemia (APL) has been found to be sensitive in vitro and in vivo to the retinoid all trans retinoic acid (ATRA).
  • In contrast to APL, other forms of AML are either nonresponsive or show blunted responses to ATRA.
  • We evaluated if the inhibitor of HDAC activity, valproic acid (VPA), could mimic or enhance retinoid sensitivity in the AML cell line, OCI/AML-2, and clinical samples derived from patients with AML.
  • An Affymetrix GeneChip experiment demonstrated that VPA modulated the expression of numerous genes in OCI/AML-2 cells that were not affected by ATRA including p21, a retinoid responsive gene in APL.
  • VPA induced p21 expression in OCI/AML-2 cells and the majority of the AML samples tested; this was associated with cell cycle arrest and apoptosis not seen with ATRA alone.
  • The addition of ATRA to VPA accentuated many of these responses, supporting the potential beneficial combination of these drugs in the treatment of AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Enzyme Inhibitors / pharmacology. Histone Deacetylase Inhibitors. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / enzymology. Tretinoin / pharmacology. Valproic Acid / pharmacology
  • [MeSH-minor] Cell Cycle / drug effects. Cell Cycle Proteins / drug effects. Cell Cycle Proteins / genetics. Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p21. Drug Screening Assays, Antitumor. Drug Synergism. Gene Expression Regulation. Histone Deacetylases / genetics. Humans. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Structure-Activity Relationship

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902297.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 5688UTC01R / Tretinoin; 614OI1Z5WI / Valproic Acid; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


87. de la Rubia J, Martín G, Martínez J, Lorenzo I, Sanz G, Jarque I, Moscardó F, Jiménez C, Lorente P, Camps A, Sanz MA: Peripheral blood stem cell collection after intermediate-dose cytarabine in adult patients with acute myeloblastic leukemia undergoing autologous blood stem cell transplantation in first complete remission. Int J Hematol; 2004 Aug;80(2):168-73
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral blood stem cell collection after intermediate-dose cytarabine in adult patients with acute myeloblastic leukemia undergoing autologous blood stem cell transplantation in first complete remission.
  • Different strategies for collecting peripheral blood stem cells (PBSC) for autologous blood stem cell transplantation (ABSCT) have been reported for patients with acute myeloblastic leukemia (AML).
  • We compared the clinical results of 2 consecutive protocols in 75 adult patients with AML in first complete remission who underwent ABSCT.
  • In the first 56 patients (group A), PBSC were collected after induction and/or consolidation chemotherapy courses.
  • Hematopoietic engraftment was similar in the 2 groups, with the median times to reach 0.5 x 10(9) neutrophils/L and 20 x 10(9) platelets/L being 13 days each in group A, and 12 days and 24 days, respectively, in group B.
  • Although not statistically significant, the 3-year probabilities of both relapse (31% versus 66%; P = .12) and disease-free survival (60% versus 36%; P = .1) compared favorably for group B.
  • Our study suggests that collection of PBSC after additional intensification can result in a better outcome for AML patients who undergo ABSCT.
  • [MeSH-major] Cytarabine / therapeutic use. Leukemia, Myeloid, Acute / therapy. Stem Cell Transplantation. Stem Cells / pathology
  • [MeSH-minor] Adolescent. Adult. Antimetabolites, Antineoplastic / therapeutic use. Female. Humans. Incidence. Leukapheresis. Male. Middle Aged. Recurrence. Siblings. Tissue and Organ Harvesting / methods. Transplantation Conditioning. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2003 Jan;17(1):68-75 [12529662.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):615-23 [12586797.001]
  • [Cites] Bone Marrow Transplant. 1996 Oct;18(4):693-8 [8899182.001]
  • [Cites] Leuk Res. 2003 Jan;27(1):5-12 [12479846.001]
  • [Cites] Stem Cells. 1995 Dec;13 Suppl 3:19-22 [8747984.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(10):821-6 [9404921.001]
  • [Cites] Bone Marrow Transplant. 2001 Apr;27(8):829-35 [11477440.001]
  • [Cites] Bone Marrow Transplant. 1991 May;7(5):343-9 [1676924.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2547-55 [7595706.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2194-6 [8708707.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4710-8 [9389686.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1661-7 [8102640.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(1):50-7 [10707999.001]
  • [Cites] Leukemia. 1997 Sep;11(9):1533-9 [9305609.001]
  • [Cites] Bone Marrow Transplant. 1998 Feb;21(4):375-82 [9509972.001]
  • [Cites] Bone Marrow Transplant. 1997 Sep;20(6):465-71 [9313879.001]
  • [Cites] Bone Marrow Transplant. 2002 May;29(10):825-32 [12058232.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Haematologica. 1999 Feb;84(2):125-32 [10091410.001]
  • [Cites] Exp Hematol. 1989 Nov;17(10):991-6 [2572443.001]
  • [Cites] Stat Med. 1993 Apr 30;12(8):737-51 [8516591.001]
  • [Cites] Leukemia. 2003 Jan;17(1):60-7 [12529661.001]
  • (PMID = 15481447.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


88. Zhu HY, DA WM, Gao CJ, Wang FF, Han XP, Li HH, Huang WR, Zhang YZ, Wang SH, Bo J, Jing Y, Jin HJ: [Effects of recombinant human interleukin 11 and granulocyte colony stimulating factor in mobilization for autologous peripheral blood stem cell transplantation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr;16(2):345-9
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 16 patients with non-Hodgkin's lymphoma or acute myeloblastic leukemia were given myelosuppressive chemotherapy, then were mobilized by using rhG-CSF 5 microg/(kg.d) for median 5.5 days and rhIL-11 50 microg/(kg.d) for median 4 days (experimental group) or rhG-CSF 5 microg/(kg.d) alone for median 5.5 days (control group).
  • After APBSCT, the median time for neutrophil count>or=0.5x10(9)/L and the median time for platelet count>or=20x10(9)/L were 10.5 and 11.5 days in experimental group, while were 13 and 13 days in control group, respectively.
  • These symptoms were well tolerated and overcome with drug withdrawal.
  • It is concluded that the regimen of rhIL-11 in combination with rhG-CSF after myelosuppressive chemotherapy to mobilize PBSC is efficient and safe with rapid hematologic reconstitution and less platelet transfusions after APBSCT were used.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18426662.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-11; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


89. Siitonen T, Mäntymaa P, Säily M, Savolainen E, Koistinen P: Etoposide-induced apoptosis is not associated with the fas pathway in acute myeloblastic leukemia cells. Leuk Res; 2000 Apr;24(4):281-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etoposide-induced apoptosis is not associated with the fas pathway in acute myeloblastic leukemia cells.
  • Two subclones of the OCI/AML-2 cell line, etoposide-sensitive (ES) and etoposide-resistant (ER), established by the authors, were used as models.
  • We investigated whether the Fas pathway is involved in etoposide-induced apoptosis in acute myeloblastic leukemia (AML).
  • The Fas-resistant phenotype of the AML cells was converted to a Fas-sensitive one by cycloheximide (CHX) suggesting the presence of an inhibitory protein of the Fas pathway in the cells.
  • In conclusion, etoposide-induced apoptosis is not mediated by the Fas pathway in AML.
  • [MeSH-major] Antigens, CD95 / physiology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Etoposide / pharmacology. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10713325.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antineoplastic Agents; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 6PLQ3CP4P3 / Etoposide; 98600C0908 / Cycloheximide
  •  go-up   go-down


90. Olcay L, Aribaş BK, Gökçe M: A patient with acute myeloblastic leukemia who presented with conus medullaris syndrome and review of the literature. J Pediatr Hematol Oncol; 2009 Jun;31(6):440-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with acute myeloblastic leukemia who presented with conus medullaris syndrome and review of the literature.
  • In childhood, the conus medullaris syndrome owing to leukemia is rare.
  • Here, a 12-year-old boy with acute myeloblastic leukemia, maxillary mass, and conus medullaris syndrome is reported.
  • A biopsy from the maxillary mass revealed "granulocytic sarcoma."
  • Lumbosacral magnetic resonance imaging revealed clumped and thickened cauda equina nerve roots, epidural and periradicular diffuse soft tissue, which was enhanced with gadolinium.
  • Chemotherapy and local radiotherapy for both the face and the spine, yielded bone marrow remission and abatement in neurologic and radiologic findings, but he developed bone marrow relapse and died because of sepsis.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Spinal Cord Compression / etiology
  • [MeSH-minor] Antigens, CD / metabolism. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Child. Combined Modality Therapy. Face / pathology. Flow Cytometry. Humans. Magnetic Resonance Imaging. Male. Radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648794.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 34
  •  go-up   go-down


91. Gutierrez JA, Pan YX, Koroniak L, Hiratake J, Kilberg MS, Richards NG: An inhibitor of human asparagine synthetase suppresses proliferation of an L-asparaginase-resistant leukemia cell line. Chem Biol; 2006 Dec;13(12):1339-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An inhibitor of human asparagine synthetase suppresses proliferation of an L-asparaginase-resistant leukemia cell line.
  • Drug resistance in lymphoblastic and myeloblastic leukemia cells is poorly understood, with several lines of evidence suggesting that resistance can be correlated with upregulation of human asparagine synthetase (hASNS) expression, although this hypothesis is controversial.
  • These observations represent direct evidence that potent hASNS inhibitors may prove to be effective agents for the clinical treatment of acute lymphoblastic leukemia.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 1999 Dec 7;38(49):16146-57 [10587437.001]
  • [Cites] Annu Rev Biochem. 2006;75:629-54 [16756505.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26 [11259830.001]
  • [Cites] Biochemistry. 2001 May 15;40(19):5655-64 [11341830.001]
  • [Cites] Biochem J. 2001 Jul 1;357(Pt 1):321-8 [11415466.001]
  • [Cites] Nat Struct Biol. 2001 Aug;8(8):689-94 [11473259.001]
  • [Cites] Biochem J. 2001 Aug 15;358(Pt 1):59-67 [11485552.001]
  • [Cites] Biochemistry. 2001 Sep 18;40(37):11168-75 [11551215.001]
  • [Cites] Annu Rev Biochem. 2001;70:149-80 [11395405.001]
  • [Cites] Methods Enzymol. 2002;354:260-71 [12418233.001]
  • [Cites] Arch Biochem Biophys. 2003 May 1;413(1):23-31 [12706338.001]
  • [Cites] Org Lett. 2003 Jun 12;5(12):2033-6 [12790521.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Sep 26;55(10):1293-302 [14499708.001]
  • [Cites] Biochemistry. 1969 Jun;8(6):2681-5 [5799144.001]
  • [Cites] J Biol Chem. 1969 Aug 10;244(15):4112-21 [4895361.001]
  • [Cites] Annu Rev Pharmacol. 1970;10:421-40 [4911021.001]
  • [Cites] Biochem Pharmacol. 1969 Oct;18(10):2578-80 [4935103.001]
  • [Cites] Cancer. 1971 Oct;28(4):819-24 [5286444.001]
  • [Cites] J Biol Chem. 1972 Oct 25;247(20):6708-19 [5076775.001]
  • [Cites] Biochem Biophys Res Commun. 1973 Apr 2;51(3):529-35 [4512981.001]
  • [Cites] J Biol Chem. 1973 Jun 10;248(11):3997-4002 [4145324.001]
  • [Cites] Biochem Pharmacol. 1975 Dec 1;24(23):2177-85 [1212266.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Anal Biochem. 1976 Dec;76(2):423-30 [11707.001]
  • [Cites] Cancer Treat Rep. 1976 Oct;60(10):1493-557 [14784.001]
  • [Cites] Cancer Treat Rep. 1979 Jun;63(6):1095-108 [38003.001]
  • [Cites] Cancer Res. 1979 Oct;39(10):3893-6 [383278.001]
  • [Cites] Methods Enzymol. 1979;63:103-38 [502857.001]
  • [Cites] Ann Occup Hyg. 1980;23(1):27-33 [6445702.001]
  • [Cites] Arch Biochem Biophys. 1985 Mar;237(2):335-46 [2858178.001]
  • [Cites] Anal Biochem. 1987 Mar;161(2):438-41 [3495203.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1988;61:201-301 [3281418.001]
  • [Cites] Anal Biochem. 1988 Apr;170(1):220-7 [3389513.001]
  • [Cites] Leukemia. 1989 Apr;3(4):294-7 [2564453.001]
  • [Cites] Biochemistry. 1990 Jan 16;29(2):366-72 [1967948.001]
  • [Cites] J Comput Aided Mol Des. 1990 Mar;4(1):1-105 [2197373.001]
  • [Cites] Biochemistry. 1991 Jun 25;30(25):6135-41 [1676298.001]
  • [Cites] J Comput Aided Mol Des. 1991 Feb;5(1):55-80 [2072126.001]
  • [Cites] Anal Biochem. 1991 May 1;194(2):268-77 [1677799.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1992 May;14(2):136-9 [1530118.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1993;66:203-309 [8430515.001]
  • [Cites] Biochemistry. 1994 Jan 25;33(3):675-81 [7904828.001]
  • [Cites] J Biol Chem. 1994 Mar 11;269(10):7450-7 [7907328.001]
  • [Cites] J Biol Chem. 1994 Oct 28;269(43):26789-95 [7929415.001]
  • [Cites] Biol Pharm Bull. 1996 Nov;19(11):1518-20 [8951178.001]
  • [Cites] Am J Physiol. 1997 May;272(5 Pt 1):C1691-9 [9176161.001]
  • [Cites] Nat Struct Biol. 1998 Jan;5(1):15-9 [9437423.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1998;72:87-144 [9559052.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1998;72:145-98 [9559053.001]
  • [Cites] Biochemistry. 1998 Sep 22;37(38):13230-8 [9748330.001]
  • [Cites] Bioorg Med Chem. 1998 Oct;6(10):1935-53 [9839023.001]
  • [Cites] Biochemistry. 1999 Mar 23;38(12):3677-82 [10090755.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):291-9 [15665306.001]
  • [Cites] Curr Opin Chem Biol. 2005 Feb;9(1):25-30 [15701449.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4223-5 [15718422.001]
  • [Cites] Arch Biochem Biophys. 2005 Aug 1;440(1):18-27 [16023613.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2005;6:261-86 [16124862.001]
  • [Cites] Br J Haematol. 2006 Mar;132(6):740-2 [16487174.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4244-9 [16497975.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7975-9 [10713115.001]
  • (PMID = 17185229.001).
  • [ISSN] 1074-5521
  • [Journal-full-title] Chemistry & biology
  • [ISO-abbreviation] Chem. Biol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK052064; United States / NIDDK NIH HHS / DK / R01 DK059315; United States / NIDDK NIH HHS / DK / DK52064; United States / NIDDK NIH HHS / DK / DK59315
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids, Sulfur; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; EC 3.5.1.1 / Asparaginase; EC 6.3.1.1 / Aspartate-Ammonia Ligase
  • [Other-IDs] NLM/ NIHMS447417; NLM/ PMC3608209
  •  go-up   go-down


92. Struhal W, Oberndorfer S, Lahrmann H, Lindeck-Pozza E, Hess B, Nussgruber V, Pöhnl R, Dobner T, Grisold W: Myeloid sarcoma in the central nervous system: case report and review of the literature. Acta Clin Croat; 2008 Mar;47(1):19-24
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid sarcoma in the central nervous system: case report and review of the literature.
  • Myeloid sarcomas are rare manifestations of mainly myeloblastic leukemia.
  • A case is added herewith and a review was performed to investigate clinical characteristics and treatment options of central nervous system myeloid sarcoma.
  • A 61-year-old female with acute myeloblastic leukemia (FAB M5) and progressive left sided hemiparesis showed a right parieto-occipital epidural lesion mimicking meningioma.
  • Partial resection was performed to reveal a myeloid sarcoma.
  • Reviewing the literature we identified 44 cases with sufficient description of the diagnosis, treatment and follow up to one year.
  • In these patients different treatment regimens were applied.
  • However, when systemic chemotherapy or irradiation was included in the treatment regimen, patients showed the best 1-year survival proportion.
  • [MeSH-major] Brain Neoplasms / diagnosis. Leukemia, Myeloid, Acute / diagnosis. Neoplasms, Multiple Primary. Occipital Lobe. Parietal Lobe. Sarcoma, Myeloid / diagnosis

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18714643.001).
  • [ISSN] 0353-9466
  • [Journal-full-title] Acta clinica Croatica
  • [ISO-abbreviation] Acta Clin Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 20
  •  go-up   go-down


93. Koc Y, Oyan B, Kars A, Tekuzman G, Canpinar H, Kansu E: A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia. Hematol Oncol; 2004 Jun;22(2):43-53
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
  • Mitoxantrone (MTZ) has been shown to be effective in the treatment of newly diagnosed acute myeloblastic leukemia (AML).
  • The objective of this randomized study was to evaluate the impact of mode of administration of MTZ on the response and recurrence rates in newly diagnosed patients with AML and to compare the toxicity patterns associated with bolus and continuous infusion (CI) of MTZ.
  • From March 1987 to March 1994, 40 newly diagnosed patients with AML were randomized to receive either bolus or CI-MTZ, administered for 3 days at 10 mg/m2/day in combination with CI-cytarabine for 7 days at 100 mg/m2/day.
  • Patients achieving complete remission (CR) received two consolidation cycles followed by monthly maintenance cycles, aiming a total of 12 cycles of chemotherapy.
  • There were no significant differences in rates of early death and time to myeloid recovery between the two groups.
  • After 11 years from the initiation of the study, median disease-free survival (DFS) in bolus and CI groups were 19 and 29 months after a median follow-up of 10 and 14 months, respectively.
  • Mild asymptomatic cardiotoxicity associated with a decrease of 10 to 20% in the ejection fraction occurred in a patient in CI-MTZ arm and in two patients in the bolus arm.
  • Development of new anti-leukemia agents with novel treatment approaches is still needed to improve the high relapse rates in patients with AML who do not have an HLA-matched donor.
  • [MeSH-major] Cytarabine / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Mitoxantrone / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Remission Induction. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 John Wiley & Sons, Ltd.
  • (PMID = 15386563.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Review
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone
  • [Number-of-references] 33
  •  go-up   go-down


94. Mabed M, Aref S, Aladle DA: Hepatocellular carcinoma of a short malignant transformation time in a patient with acute myeloblastic leukemia. Ann Hematol; 2003 May;82(5):318-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma of a short malignant transformation time in a patient with acute myeloblastic leukemia.
  • Few cases of hepatocellular carcinoma (HCC) have been described during the course of acute leukemia.
  • The chemotherapy given may be responsible for the development of HCC in such cases.
  • Here, we present a case of a patient with acute myeloblastic leukemia who developed HCC of a short malignant transformation time, which does not seem to be related to associated hepatitis or to the chemotherapy given.
  • This may draw attention to the possible contributory role of certain products secreted by the myeloid leukemic cells such as the hepatocyte growth factor (HGF) in increasing the risk of developing HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Cell Transformation, Neoplastic. Leukemia, Myeloid, Acute / pathology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Drug-Induced Liver Injury / complications. Growth Substances. Humans. Male. Middle Aged. Time Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12709828.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Growth Substances
  •  go-up   go-down


95. Nayak S, Shen M, Bunaciu RP, Bloom SE, Varner JD, Yen A: Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells. Leuk Lymphoma; 2010 Sep;51(9):1734-47
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells.
  • Arsenic trioxide (ATO) synergistically promotes all trans retinoic acid (ATRA)-induced differentiation of PML-RARalpha negative HL-60 myeloblastic leukemia cells.
  • In PML-RARalpha positive myeloid leukemia cells, ATO is known to cause degradation of PML-RARalpha with subsequent induced myeloid differentiation.
  • Compared to ATRA-treated cells, the ATRA plus ATO-treated cells progressed more slowly through the cell cycle as detected by a slower rate of accumulation in G2/M following nocodazole treatment.
  • In summary, our results indicate that ATO in conjunction with ATRA is of potential chemotherapeutic use in PML-RARalpha negative leukemias.

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20615082.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA033505; United States / NCI NIH HHS / CA / CA 033505
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ NIHMS790261; NLM/ PMC4896300
  •  go-up   go-down


96. Shibuya K, Kuwaki T, Akahori H, Kato T, Miyazaki H: Pegylated recombinant human megakaryocyte growth and development factor suppresses the development of megakaryoblastic leukemia in mice. Leuk Res; 2004 Sep;28(9):941-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pegylated recombinant human megakaryocyte growth and development factor suppresses the development of megakaryoblastic leukemia in mice.
  • We examined the effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on the development of L-8057, a murine megakaryoblastic leukemia that expresses the thrombopoietin receptor c-Mpl, in mice.
  • L-8057 cells harvested from PEG-rHuMGDF-treated leukemic mice had decreased ability to generate leukemic colonies in vitro as well as to induce leukemia in vivo.
  • PEG-rHuMGDF administration also resulted in prolonged survival of mice transplanted with a c-Mpl-expressing erythroleukemia, but had no effect on survival of mice transplanted with a myeloblastic leukemia that does not possess c-Mpl.
  • Thus, PEG-rHuMGDF suppresses the development of c-Mpl-expressing leukemia in vivo in mice.
  • [MeSH-major] Leukemia, Megakaryoblastic, Acute / drug therapy. Polyethylene Glycols / pharmacology. Recombinant Proteins / pharmacology. Thrombopoietin / pharmacology
  • [MeSH-minor] Animals. Binding Sites. Cell Line, Tumor. Humans. Liver. Male. Mice. Mice, Inbred C3H. Neoplasm Transplantation. Oncogene Proteins / analysis. Oncogene Proteins / metabolism. Organ Size / drug effects. Receptors, Cytokine / analysis. Receptors, Cytokine / metabolism. Receptors, Thrombopoietin. Spleen. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15234571.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mpl protein, mouse; 0 / Oncogene Proteins; 0 / Receptors, Cytokine; 0 / Receptors, Thrombopoietin; 0 / Recombinant Proteins; 0 / polyethylene glycol-recombinant human megakaryocyte growth and development factor; 30IQX730WE / Polyethylene Glycols; 9014-42-0 / Thrombopoietin
  •  go-up   go-down


97. Ontachi Y, Asakura H, Funada H, Takami A, Saito M, Morishita E, Yamazaki M, Mizutani T, Kaneda M, Ito T, Nakao S: An idiopathic skin eruption resembling a butterfly rash in a septic patient with disseminated intravascular coagulation following bone marrow transplantation. Blood Coagul Fibrinolysis; 2004 Apr;15(3):255-9
MedlinePlus Health Information. consumer health - Sepsis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 31-year-old man who underwent chemotherapy and bone marrow transplantation to treat acute myeloblastic leukemia was admitted to our department complaining of high fever and hypotension.
  • Following treatment with blood transfusion, anticoagulant, antibiotics, respirator and continuous arteriovenous hemofiltration and dialysis, the patient's condition gradually improved.
  • The eruptions on his face first observed at admission progressed with a worsening of his disseminated intravascular coagulation (DIC), and subsided with an improvement in his DIC.
  • The skin necrosis in purpura fulminans often begins in the distal extremities.
  • But our patient developed this uncommon skin eruption on his face.
  • [MeSH-minor] Adult. Face. Fibrin / metabolism. Humans. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / therapy. Male. Necrosis. Purpura, Schoenlein-Henoch / etiology. Purpura, Schoenlein-Henoch / pathology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Rashes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15060423.001).
  • [ISSN] 0957-5235
  • [Journal-full-title] Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • [ISO-abbreviation] Blood Coagul. Fibrinolysis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9001-31-4 / Fibrin
  •  go-up   go-down


98. Brassat D, Recher C, Waubant E, Le Page E, Rigal-Huguet F, Laurent G, Edan G, Clanet M: Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology; 2002 Sep 24;59(6):954-5
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.
  • The authors report a patient with severe secondary progressive MS who responded to mitoxantrone but developed a fatal acute myeloblastic leukemia 15 months after completion of mitoxantrone therapy.
  • Therapy-related acute leukemia (TRAL) in relation with mitoxantrone is rare; this patient was the first case among a cohort of 802 French MS patients treated with mitoxantrone.
  • [MeSH-major] Leukemia, Myeloid, Acute / chemically induced. Mitoxantrone / adverse effects. Multiple Sclerosis / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurology. 2003 Apr 22;60(8):1399-400; author reply 1400 [12707461.001]
  • (PMID = 12297591.001).
  • [ISSN] 0028-3878
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


99. Belot V, Perrinaud A, Corven C, de Muret A, Lorette G, Machet L: [Adult idiopathic neutrophilic eccrine hidradenitis treated with colchicine]. Presse Med; 2006 Oct;35(10 Pt 1):1475-8
Hazardous Substances Data Bank. COLCHICINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hidradénite eccrine neutrophilique idiopathique de l'adulte d'évolution prolongée traitée par colchicine.
  • INTRODUCTION: Neutrophilic eccrine hidradenitis (NEH) is a rare disease belonging to the group of neutrophilic dermatoses.
  • It occurs mostly in patients receiving chemotherapy for acute myeloblastic leukemia or, less frequently, another malignancy.
  • CASE REPORT: We report the case of a 56-year-old woman with no remarkable medical history who developed an erythematous papular facial eruption.
  • DISCUSSION: This case is particular because NEH was not associated with malignant hematologic disease, solid cancer, chemotherapy, fever or any other disease, after a follow-up of 22 months.
  • The second particularity is the length of the eruption, which required colchicine treatment.
  • Clinical improvement occurred within 1 month.
  • Because hematologic malignancies can in some cases be preceded by neutrophilic dermatitis, clinical follow-up is recommended in adults.
  • [MeSH-major] Colchicine / therapeutic use. Gout Suppressants / therapeutic use. Hidradenitis / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17028536.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Gout Suppressants; SML2Y3J35T / Colchicine
  •  go-up   go-down


100. Paydaş S, Zorludemir S, Sahin B: Vasculitis and leukemia. Leuk Lymphoma; 2000 Dec;40(1-2):105-12
MedlinePlus Health Information. consumer health - Vasculitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vasculitis and leukemia.
  • Vasculitis may accompany neoplasias and be of paraneoplastic type or associated with drugs used in patient treatment.
  • We evaluated skin biopsies of twenty-eight cases with vasculitis accompanying leukemias reviewed and clinical outcome was evaluated.
  • Eleven of the 28 cases had paraneoplastic vasculitis and 17 had vasculitis associated with various drugs including chemotherapy, cytokines and antibacterial agents.
  • Paraneoplastic vasculitis was seen in 3 cases with chronic myelocytic leukemia in blastic phase, 5 patients with acute myeloblastic leukemia, and 3 with myelodysplastic syndrome.
  • Drugs responsible for the 17 cases of vasculitis included hydroxyurea, vincristine, cytosine-arabinoside, methotrexate, all-trans retinoic acid, granulocyte-colony stimulating factor, interferon and antibiotics.
  • Paraneoplastic vasculitis is not rare in leukemias and may be a manifestation of the blastic phase of chronic myeloid leukemia.
  • Furthermore paraneoplastic vasculitis can be fatal in myelodysplastic syndromes and may be present clinically before the specific diagnosis is made.
  • Drugs used in routine therapy may be the cause of the vasculitis, thus skin biopsy should be performed in all cutaneous lesions in patients with hemopoietic neoplasias.
  • [MeSH-major] Leukemia / complications. Vasculitis / etiology

  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426610.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement